Fever of Unknown Origin {#Sec1}
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Differential Diagnosis {#Sec2}
----------------------

This list is not exclusive, but highlights some important causes of FUO after the common causes of fever have been excluded:

### INFECTIONS {#FPar1}

---**TB** (pulmonary, extrapulmonary, miliary), **abscess** (liver, splenic, perinephric, psoas, diverticular, pelvis), **osteomyelitis**, **endocarditis**, **prosthetic associated infections**

### NEOPLASTIC {#FPar2}

---**hematologic** (lymphoma, leukemia, multiple myeloma, myelodysplastic syndrome), **solid tumors** (renal cell, hepatoma)

### COLLAGEN-VASCULAR {#FPar3}

---**vasculitis** (giant cell arteritis, Still's disease, polyarteritis nodosa, Takayasu's arteritis, granulomatosis with polyangiitis, mixed cryoglobulinemia), **lupus**, **rheumatoid arthritis**

### DRUGS {#FPar4}

---**antimicrobials** (sulfonamides, penicillins, nitrofurantoin, antimalarials), **antihistamines**, **antiepileptics** (barbiturate, phenytoin), **NSAIDs**/**ASA**, **antihypertensives** (hydralazine, methyldopa), **antiarrhythmics** (quinidine, procainamide), **antithyroid**, **iodides**, **quinine**, **illicit** (cocaine)

### UNCOMMON CAUSES OF FUO {#FPar5}

---**central fever**, **endocrine** (hypothalamic dysfunction, hyperthyroidism, pheochromocytoma, adrenal insufficiency), **infections** (dental abscess, Q fever, leptospirosis, psittacosis, tularemia, melioidosis, syphilis, gonococcemia, chronic meningococcemia, Whipple's disease, yersiniosis, brucellosis), **hereditary periodic fever syndromes** (familial Mediterranean fever, PFAPA syndrome \[Periodic Fever with Aphthous Stomatitis and Adenitis\], TNFR-1-associated periodic syndrome, hyper-IgD syndrome, Muckle--Wells syndrome, familial cold autoinflammatory syndrome), **alcoholic hepatitis**, **hematoma**, **factitious fever**

Pathophysiology {#Sec3}
---------------

### Definitions {#FPar6}

**[fever of unknown origin]{.smallcaps}** (**FUO**)**FUO**---≥ 38.3 °C \[≥101 °F\], duration ≥3 weeks, diagnosis uncertain after 3 days in hospital or three outpatient visits**[nosocomial]{.smallcaps}** **FUO**---hospitalized patients, ≥38.3 °C \[≥101 °F\], diagnosis uncertain after 3 days and infection not present or incubating on admission**[immune]{.smallcaps}**-**[deficient]{.smallcaps}** (**[neutropenic]{.smallcaps}**) **FUO**--- \> 38.3 °C \[≥101 °F\], \>3 days, neutrophil count ≤500/mm^3^. See p. 260 for details**HIV**-**[related]{.smallcaps}** **FUO**---HIV patients, ≥38.3 °C \[≥101 °F\], duration ≥3 weeks for outpatients or ≥3 days for inpatients**[fever]{.smallcaps}**, **NYD**---persistent fever that has not yet met the definition for FUO

Clinical Features {#Sec4}
-----------------

### HISTORY {#FPar7}

---pattern and duration of fever, associated symptoms (cough, dyspnea, hemoptysis, chest pain, diarrhea, abdominal pain, dysuria, urethral discharge, hematuria, neck stiffness, headache), rash (palpable purpura, exanthem), exposure (food, water, plants, animals, insects, infected human secretions), weight loss, night sweats, travel history, sexual history, HIV risk factors, immunizations, past medical history (rheumatologic disorders, malignancy, alcohol), medications

### PHYSICAL {#FPar8}

---vitals (tachycardia, tachypnea, hypotension, fever, hypoxemia), oral ulcers, lymphadenopathy, nuchal rigidity, respiratory and cardiac examination (murmurs), temporal artery, abdominal examination (hepatosplenomegaly), prostate examination, skin lesions (morphology, distribution), tick bite marks, joint examination

Investigations {#Sec5}
--------------

### BASIC {#FPar9}

**[labs]{.smallcaps}**---CBCD, lytes, urea, Cr, AST, ALT, ALP, bilirubin, LDH, CK, serum protein electrophoresis, urinalysis, ESR, CRP, ANA, ENA, RF, C3, C4, ANCA, cryoglobulin**[microbiology]{.smallcaps}**---blood C&S (including *Mycobacteria*), sputum Gram stain/AFB/C&S, urine C&S, stool C&S, O&P, serology (HBV, HCV, HIV, monospot, CMV IgM, endemic fungi)**[imaging]{.smallcaps}**---CXR, echocardiogram (if suspect endocarditis), CT chest/abd/pelvis as guided by symptoms, FDG-PET (may be useful for identifying sites of inflammation and malignancy in FUO)

### SPECIAL {#FPar10}

**ECGT** **[uberculin skin test]{.smallcaps}[biopsy]{.smallcaps}**---affected tissue (e.g. bone marrow biopsy)

Diagnosis and Prognostic Issues {#Sec6}
-------------------------------

### DIAGNOSIS {#FPar11}

---the most important diagnostic strategy is a careful history and physical examination with frequent reassessment

### PROGNOSIS {#FPar12}

---up to 30--50% will not have a diagnosis despite detail workup; 5-year mortality in those without a diagnosis is 3%

Management {#Sec7}
----------

### EMPIRIC ANTIBIOTICS {#FPar13}

---ONLY if suspect infectious etiology and therapy cannot be delayed due to severity of patient's disease (see EMPIRIC ANTIBIOTICS p. 289). In general, therapeutic trials of antimicrobials or steroids are discouraged

**TREAT UNDERLYING CAUSE**

Fever and Rash {#Sec8}
==============

Differential Diagnosis {#Sec9}
----------------------

### INFECTIONS {#FPar15}

**[gram]{.smallcaps}**-**[positive cocci]{.smallcaps}**---scarlet fever, toxic shock syndrome, staphylococcal scalded skin syndrome, acute rheumatic fever (erythema marginatum, subcutaneous nodules)**[gram]{.smallcaps}**-**[negative cocci]{.smallcaps}**---meningococcemia (purpura), disseminated gonococcal infection**[gram]{.smallcaps}**-**[negative bacilli]{.smallcaps}**---*Salmonella typhi*, *Pseudomonas* (ecythema gangrenosum), *Vibrio vulnificus***[endocarditis]{.smallcaps}[spirochetes]{.smallcaps}**---*Borrelia burgdorferi* (Lyme erythema migrans), *Treponema pallidum* (chancre, secondary syphilis)**[rickettsial]{.smallcaps}**---Rocky Mountain spotted fever, ehrlichiosis, typhus**[viral exanthem]{.smallcaps}**---acute HIV, mononucleosis, rubella, measles, roseola, erythema infectiosum, chickenpox, shingles, coxsackie virus, echovirus**[fungal]{.smallcaps}**---*Blastomyces*, *Coccidioides*, *Histoplasma*

### RHEUMATOLOGIC {#FPar16}

**[seropositive]{.smallcaps}**---lupus, dermatomyositis**[seronegative]{.smallcaps}**---inflammatory bowel disease, reactive arthritis**[vasculitis]{.smallcaps}**---granulomatosis with polyangiitis, polyarteritis nodosa**B** **[ehcet]{.smallcaps}**'**[s disease]{.smallcaps}**

### MALIGNANCY {#FPar17}

---lymphoma, leukemia, metastatic, paraneoplastic

### MEDICATIONS {#FPar18}

---penicillins, cephalosporins, sulfas, barbiturates, phenytoin, procainamide, quinidine

### OTHERS {#FPar19}

---sarcoidosis, erythema nodosum; Sweet's syndrome (acute febrile neutrophilic dermatosis)

Clinical Features {#Sec10}
-----------------

### SETTINGS {#FPar20}

**[age]{.smallcaps}**---viral exanthems, scarlet fever, and acute rheumatic fever are more likely in children. Mononucleosis is more common in young adults**[season]{.smallcaps}**---tick-borne diseases are more common in spring and summer. Coxsackie virus and echovirus are more common in summer and fall. Meningococcus and parvovirus are more common in winter and spring**[geographic location]{.smallcaps}**---Lyme disease in Pacific northwest, the Midwest, and the northeast USA and some southern Canadian locations. RMSF in south-central and Atlantic states. Ehrlichiosis in midwestern, south-central, and southeastern states. Tularemia in western, southeastern, and south-central states and Canada. Relapsing fever (*Borrelia hermsii*) in mountainous areas of the western USA. Endemic fungal infections include *Blastomyces dermatitidis* (southeastern states, Manitoba, and Ontario), *Coccidioides immitis* (southwestern states), and *Histoplasma capsulatum* (Mississippi, Ohio River valleys, and Quebec)

### HISTORY {#FPar21}

---pattern and duration of fever, associated symptoms (cough, dyspnea, chest pain, diarrhea, abdominal pain, dysuria, urethral discharge, neck stiffness, headache), rash (prodrome, location, progression, treatment), exposure (food, water, plants, animals, infected human secretions), weight loss, night sweats, travel history, sexual history, immunizations, past medical history (rheumatologic disorders, malignancy), medications

### PHYSICAL {#FPar22}

---vitals (tachycardia, tachypnea, hypotension, fever, hypoxemia), oral ulcers, lymphadenopathy, nuchal rigidity, respiratory and cardiac examination (murmurs), abdominal examination (hepatosplenomegaly), skin lesions (morphology, distribution), tick bite eschar, joint examination

Investigations {#Sec11}
--------------

### BASIC {#FPar23}

**[labs]{.smallcaps}**---CBCD, lytes, urea, Cr, AST, ALT, ALP, bilirubin, ESR, urinalysis**[microbiology]{.smallcaps}**---blood C&S, sputum Gram stain/AFB/C&S, urine C&S, monospot test, CMV IgM, EBV, HIV, and other serologies (e.g. rickesttsial serology)

### SPECIAL {#FPar24}

**[lumbar puncture]{.smallcaps}**---if suspect meningococcus**[skin biopsy]{.smallcaps}**---dermatology consult**[inflammatory workup]{.smallcaps}**---CRP, ANA, ENA

Management {#Sec12}
----------

### ISOLATION PRECAUTIONS {#FPar25}

---droplet/airborne plus contact precautions for uncertain diagnosis; for purpura with bacterial sepsis, institute droplet and contact isolation precautions. See p. 304 for more details

**TREAT UNDERLYING CAUSE**

Specific Entities {#Sec13}
-----------------

### RICKETTSIAL INFECTIONS (WITHIN NORTH AMERICA) {#FPar27}

**[themes]{.smallcaps}**---all transmitted by ticks, except Q fever (*Coxiella burnetii*). All associated with a rash, myalgias, and headache, except Q fever and ehrlichiosis. All involve some degree of vasculitis and DIC as part of pathogenesis. All can be treated with doxycycline**R** **[ocky]{.smallcaps}** **M** **[ountain spotted fever]{.smallcaps}**---*Rickettsia rickettsii* transmitted by ticks. Most common in mid-Atlantic states. Macular/maculopapular rash begins on extremities and moves centrally, involves palms/soles. Treat with doxycycline**[murine typhus]{.smallcaps}**---flea vector. Rash begins centrally and moves peripherally. Treat with doxycycline or chloramphenicol**[ehrlichia]{.smallcaps}**---*E. chaffeensis* (human monocytic ehrlichiosis) transmitted by lone star tick. Peaks in May to July. Infects lymphocytes, monocytes, and neutrophils intracellularly. Fever, headache, myalgia, leukopenia, thrombocytopenia, and elevated transaminases; maculopapular or petechial rash in 1/3. Human granulocytic anaplasmosis is caused by a related *Ehrlichia* and produces similar illness without rash. Transmitted by Ixodes tick and co-infection with Lyme disease possible. Treat with doxycycline**Q** **[fever]{.smallcaps}**---*Coxiella burnetii* transmitted by respiratory spread from infected animal body fluids (e.g. cattle, sheep, goats, cats). No rash. Fever, pneumonitis, hepatitis, endocarditis, CNS symptoms. Treat with doxycycline

### LYME DISEASE {#FPar28}

**[pathophysiology]{.smallcaps}**---*Borrelia burgdorferi* transmitted by tick bite after attachment for \>24 h; think about concomitant tick borne diseases**[clinical features]{.smallcaps}**---most common tick-borne disease in USA, particularly coastal Atlantic States and California during spring and summer**[stage]{.smallcaps}** **1** (**[early]{.smallcaps}**)---first 3--30 days, erythema migrans, fever, meningismus, lymphadenopathy**[stage]{.smallcaps}** **2** (**[disseminated]{.smallcaps}**)---weeks to months, hematogenous spread with **neurological symptoms** (facial nerve palsy, lymphocytic meningitis, encephalitis, chorea, myelitis, radiculitis, peripheral neuropathy) and **carditis** (AV block, dilated cardiomyopathy); may have multiple skin lesions of erythema migrans**[stage]{.smallcaps}** **3** (**[late]{.smallcaps}**)---months to years, mono- or oligoarthritis, acrodermatitis chronica atrophicans (in Europe), progressive encephalitis, dementia. Not amenable to antibiotic therapyMay develop post-Lyme syndrome with musculoskeletal pain, neurocognitive symptoms, dysesthesias and fatigue (not amenable to antibiotic therapy)**[diagnosis]{.smallcaps}**---seology (anti-B. burgdorferi ELISA). If positive, confirm with Western blot**[prevention]{.smallcaps}**---protective clothing and tick repellants. After tick bite (\>36 h in hyperendemic area), consider *doxycycline* 200 mg × 1 dose within 72 h of the tick bite**[treatments]{.smallcaps}**---**stage 1** (*doxycycline* 100 mg PO BID × 10--21 days, or *cefuroxime* 500 mg PO BID × 10--21 days). **Lyme carditis** (*ceftriaxone* 2 g IV × 14--21 days if third degree AV block; otherwise, same as stage I with oral antibiotics). **Neurologic Lyme** (*ceftriaxone* 2 g IV × 14--21 days). **Lyme arthritis** (*doxycycline* 100 mg BID × 28 days, amoxicillin)**J** **[arisch]{.smallcaps}**--**H** **[erxheimer reaction]{.smallcaps}**---up to 15% of patients may experience transient worsening of symptoms during first 24 h of treatment. This results from the host immune response to antigen release from dying organisms (typically Lyme and syphilis) causing fever, chills, myalgias, and exacerbation of rash

### RATIONAL CLINICAL EXAMINATION SERIES: DOES THIS PATIENT HAVE ERYTHEMA MIGRANS? {#FPar29}

Sens (%)**History** (**US studies**)Systemic symptoms65Fatigue47Headache36Myalgias35Arthralgias35Fever33Pruritus33Stiff neck31History of a tick bite26Dysesthesia20Nausea and vomiting11**Physical** (**US studies**)Solitary lesion81Lymphadenopathy22Multiple lesions21Central clearing of rash19 **APPROACH**---"no single component of the history or physical examination emerges as one that makes the diagnosis of erythema migrans highly likely. These signs and symptoms have not been examined in combination. Laboratory testing has limited utility. In endemic areas, the combination of history of a tick bite, a solitary lesion of appropriate size, morphology and presence of systemic symptoms is consistent with erythema migrans. In non-endemic areas, these same factors are also suggestive of this diagnosis and should prompt further investigation"

JAMA 2007 297:23

### BABESIOSIS (malaria like; does not cause rash) {#FPar30}

**[pathophysiology]{.smallcaps}**---*B. microti* (USA) or *B. divergens* (Europe) transmitted by Ixodes ticks (which also transmit Lyme disease and *Ehrlichia*) → fever, chills, sweats, malaise, myalgias, arthralgias, headache 5--33 days after, particularly in immunosuppressed individuals**[clinical features]{.smallcaps}**---endemic in southern New England, southern New York, Wisconsin, and Minnesota**[diagnosis]{.smallcaps}**---blood smear ('Maltese cross' formations, not seen in malaria), PCR, serology**[treatments]{.smallcaps}**---atovaquone plus azithromycin

### Related Topic {#FPar31}

Exanthematous Lesions (p. 413)

Fever and Joint Pain {#Sec14}
====================

See JOINT PAIN AND FEVER (p. 312)

Sepsis {#Sec15}
======

See SEPSIS (p. 108)

Febrile Neutropenia {#Sec16}
===================

IDSA Guidelines 2011

Differential Diagnosis {#Sec17}
----------------------

### BACTERIAL {#FPar32}

**[gram positive]{.smallcaps}**---*S. aureus*, coagulase-negative staphylococci, *Streptococcus pneumoniae*, corynebacterium**[gram negative]{.smallcaps}**---*Enterobacter*, *Escherichia coli*, *Klebsiella pneumoniae*, *Pseudomonas*, *C. difficile*, anaerobes**TB**

### VIRAL {#FPar33}

---HSV, VZV, CMV, EBV, HHV6, enterovirus, RSV, influenza and other respiratory viruses

### FUNGAL {#FPar34}

---*Candida, Aspergillus*, *Cryptococcus*, *Fusarium*

### REACTIVATION OF LATENT INFECTION {#FPar35}

---*Histoplasma*, *Coccidioides*, *Toxoplasma*, tuberculosis

Pathophysiology {#Sec18}
---------------

### DEFINITION {#FPar36}

---single temp ≥38.3 °C \[101 °F\] or ≥38 °C \[100.4 °F\] for \>1 h, ANC \<0.5 × 10^9^/L or \<1.0 × 10^9^/L + expected nadir \<0.5 × 10^9^/L

### ABSOLUTE NEUTROPHIL COUNT (ANC) {#FPar37}

---neutrophils + bands

### PATHOGENESIS {#FPar38}

---chemotherapy-induced injury to mucosal barriers, immune defects due to drugs or underlying disease and invasive devices. With the attenuated immune response, patients may be relatively asymptomatic until they decompensate due to overwhelming infection. Fever is sometimes the only warning sign and should always be taken seriously in patients at risk of developing neutropenia

### NEUTROPENIA-ASSOCIATED FEBRILE EPISODES {#FPar39}

---most commonly idiopathic; bacterial source identified in approximately 30% of episodes, usually from patient's own endogenous flora. Fungal infections replace bacterial infections in prominence after 7 days. Fever usually abates with return of neutrophils. If fever persists or returns after neutropenia resolves, consider hepatosplenic candidiasis

Clinical Features {#Sec19}
-----------------

### HISTORY {#FPar40}

---patients usually asymptomatic other than fever. Determine severity and duration of fever, associated signs and symptoms (cough, dyspnea, chest pain, diarrhea, abdominal pain, dysuria, urethral discharge, neck stiffness, headache, rash), recent chemotherapy (nadir of neutrophil counts usually 10--14 days post-treatment), weight loss, night sweats, travel history, sexual history, immunizations, past medical history (malignancy, rheumatologic disorders), medications (chemotherapy, GCSF)

### PHYSICAL {#FPar41}

---vitals (tachycardia, tachypnea, hypotension, fever, hypoxemia), oral ulcers, lymphadenopathy, nuchal rigidity, respiratory and cardiac examination (murmurs), abdominal examination (hepatosplenomegaly), skin lesions (morphology, distribution). Important sites to examine include venous access devices, sinuses, and perianal region for abscess. Digital rectal examination is not recommended as potential rectal tear and translocation of gut microbes (also avoid rectal thermometers, enemas, suppositories)

Investigations {#Sec20}
--------------

### BASIC {#FPar42}

**[labs]{.smallcaps}**---CBCD, lytes, urea, Cr, AST, ALT, ALP, bilirubin, urinalysis**[microbiology]{.smallcaps}**---blood C&S × 2 (culture peripheral blood in addition to central line ports), sputum Gram stain/AFB/C&S, urine C&S, stool C&S, O&P, *C. difficile* toxin (if diarrhea)**[imaging]{.smallcaps}**---CXR

### SPECIAL {#FPar43}

**[sinus]{.smallcaps}** **X**-**ray**

Management {#Sec21}
----------

### LOW RISK {#FPar44}

(ANC \>0.1 × 10^9^/L, peak temperature \<39 °C \[102.2 °F\], no significant symptoms or signs, no significant comorbidities, nearly normal renal and hepatic function, neutropenia ≤7 days, no dehydration, no hypotension, age \<60 years)---*ciprofloxacin* 500 mg PO BID + *amoxicillin*--*clavulanate* 500 mg PO q8h. May send home with follow-up

### HIGH RISK {#FPar45}

(anticipated prolonged \>7 days duration and profound neutropenia \[ANC ≤0.1 × 10^9^/mL\] and/or significant medical comorbid conditions such as hypotension, pneumonia, new-onset abdominal pain, or neurologic changes)---admit for intravenous antibiotics**[first line]{.smallcaps}**---one of *imipenem* 500 mg IV q6h, *meropenem* 2 g IV q8h, *ceftazidime* 2 g IV q8h, *cefepime* 2 g IV q8h, *piperacillin*/*tazobactam* 4.5 g IV q8h, *piperacillin* 3 g IV q4h plus *tobramycin* 2--2.5 mg/kg IV q8h, *clindamycin* 600 mg IV q8h plus *tobramycin* 7 mg/kg IV q24h, or *piperacillin*/*tazobactam* 4.5 g IV q8h plus *gentamicin* 2--2.5 mg/kg IV q8h**[second line]{.smallcaps}**---add ***vancomycin*** 1 g IV q12h if suspect line infection, known colonization MRSA, Gram-positive blood culture, or hypotension**[third line]{.smallcaps}**---add **antifungal** if febrile after 4--7 days and hemodynamically unstable (*fluconazole* 400 mg IV daily, *itraconazole* 200 mg IV daily, *amphotericin B* 0.5--1 mg/kg IV daily over 4 h, *caspofungin* 70 mg on first day followed by 50 mg IV daily)Unexplained persistent fever in a patient whose condition is otherwise stable rarely requires an empirical change to the initial antibiotic regimen. If an infection is identified, antibiotics should be adjusted accordingly

### GCSF SUPPORT {#FPar46}

---see TREATMENT ISSUES below

### CATHETER REMOVAL {#FPar47}

---necessary for most patients with bacteremia/candidemia with organisms other than coagulase-negative *Staphylococci*

Treatment Issues {#Sec22}
----------------

### MODIFICATION OF THERAPY DURING FIRST WEEK OF TREATMENT {#FPar48}

**[if patient becomes afebrile in]{.smallcaps}** **3**--**5** **[days]{.smallcaps}** **[known organism]{.smallcaps}**---switch to specific antibiotics**[unknown etiology and low risk]{.smallcaps}**---switch to ciprofloxacin plus amoxicillin--clavulanate after afebrile for 48 h**[unknown etiology and high risk]{.smallcaps}**---continue same antibiotics**[if persistent fever during first]{.smallcaps}** **3**--**5** **[days]{.smallcaps}** **[clinically stable by day]{.smallcaps}** **3**---continue antibiotics, stop vancomycin if cultures negative**[progressive disease by day]{.smallcaps}** **3**---change antibiotics**[febrile after day]{.smallcaps}** **5**---add antifungal

### DURATION OF ANTIBIOTIC TREATMENT {#FPar49}

**[if afebrile by day]{.smallcaps}** **3** **[stop antibiotics]{.smallcaps}**---if (1) ANC ≥0.5 × 10^9^/L for 2 consecutive days, afebrile for ≥48 h, cultures negative, and no obvious signs of infection, or if (2) ANC \<0.5 × 10^9^/L by day 7, but afebrile for 5--7 days, patient initially at low risk, and no subsequent complications**[continue antibiotics]{.smallcaps}**---if above criteria not met**[if persistent fever on day]{.smallcaps}** **3** **[stop antibiotics]{.smallcaps}**---if ANC ≥0.5 × 10^9^/L for 4--5 consecutive days**[continue antibiotics]{.smallcaps}**---if ANC \<0.5 × 10^9^/L, reassess and continue antibiotics for 2 weeks. Consider stopping therapy if no disease site is found and condition is stable

### PRE-MEDICATIONS FOR AMPHOTERICIN B {#FPar50}

---*meperidine* 50 mg IV, *acetaminophen* 2 tabs PO, *hydrocortisone* 25 mg IV 30 min before dose, and repeat × 1 1--2 h after administration

### ASCO 2006 GUIDELINE FOR GCSF USE {#FPar51}

**[primary prophylaxis]{.smallcaps}**---GCSF is recommended for the prevention of febrile neutropenia if**[high]{.smallcaps}**-**[risk patients]{.smallcaps}**---based on age (\>65), medical history (poor performance status, previous febrile neutropenia, extensive prior treatment, poor nutrition, open wounds, active infections), disease characteristics (bone marrow involvement), and myelotoxicity of the chemotherapy regimen (chemoradiation)**[chemotherapy regimens]{.smallcaps}**---20% or higher risk of febrile neutropenia or dose dense regimens**[secondary prophylaxis]{.smallcaps}**---GCSF is recommended for patients who experienced a neutropenic complication from a prior cycle of chemotherapy (in which primary prophylaxis was not received), in which a reduced dose may compromise disease-free survival overall survival, or treatment outcome**[treatment of patients with febrile neutropenia]{.smallcaps}**---GCSF should be given to those with high risk of developing complications, including expected prolonged (\>10 days) and profound (\<0.1 × 10^9^/L) neutropenia, age \>65 years, uncontrolled primary disease, pneumonia, hypotension and multi-organ dysfunction (sepsis), invasive fungal infection, being hospitalized at the time of the development of fever**[special situations]{.smallcaps}** **[stem cell transplant]{.smallcaps}**---to mobilize peripheral blood progenitor cell often in conjunction with chemotherapy. Also administered after autologous, but not allogeneic stem cell transplantation**DLBCL**---prophylactic GCSF should be given for patients with diffuse aggressive lymphoma age 65 and older treated with curative chemotherapy (CHOP or more aggressive regimens)**AML**---may be given shortly after completion of the initial induction chemotherapy to modestly decrease the duration of neutropenia**ALL**---recommended after the completion of the initial first few days of chemotherapy of the initial induction or first post-remission course, thus shortening the duration of neutropenia by approximately 1 week**MDS**---may be used to increase the ANC in neutropenic patients. Intermittent administration of CSFs may be considered in a subset of patients with severe neutropenia and recurrent infections**[post]{.smallcaps}**-**[radiation]{.smallcaps}**---GCSF should be given to patients exposed to lethal doses of total body radiotherapy, but not doses high enough to lead to certain death due to injury to other organs

J Clin Oncol 2006 24:19

Specific Entities {#Sec23}
-----------------

### NECROTIZING ENTEROCOLITIS (typhlitis) {#FPar52}

**[pathophysiology]{.smallcaps}**---mucosal injury in patients with profound neutropenia → impaired host defense → necrosis of bowel wall, involving cecum extending into ascending colon and terminal ileum**[clinical features]{.smallcaps}**---abdominal pain (especially RLQ) in neutropenic patients**[diagnosis]{.smallcaps}**---CT abd. Avoid barium enema and colonoscopy**[treatments]{.smallcaps}**---bowel rest, NG suction, IV fluids, nutritional support, broad spectrum antibiotics, GCSF. Surgical indications include peritonitis, perforation, persistent GI bleeding, or clinical deterioration

### Related Topics {#FPar53}

Chemotherapy (p. 246)

Neutropenia (p. 164)

Sepsis (p. 108)

Stem Cell Transplant (p. 201)

Fever with Travel History {#Sec24}
=========================

NEJM 2002 347:7

<http://www.cdc.gov>

Clin Infect Dis 2007 44:12

Differential Diagnosis {#Sec25}
----------------------

### FEVER WITH CNS INVOLVEMENT {#FPar54}

**[bacterial]{.smallcaps}**---meningococcal, typhoid fever, rickettsial, leptospirosis**[mycobacterial]{.smallcaps}**---tuberculosis**[viral]{.smallcaps}**---Japanese encephalitis, West Nile encephalitis, tick-borne encephalitis, poliomyelitis, rabies**[fungal]{.smallcaps}**---coccidioidomycosis**[parasitic]{.smallcaps}**---malaria, angiostrongyliasis, trypanosomiasis

### FEVER WITH RESPIRATORY INVOLVEMENT {#FPar55}

**[bacterial]{.smallcaps}**---*S. pneumoniae*, mycoplasma, Legionella, Q fever, typhoid fever, scrub typhus**[mycobacterial]{.smallcaps}**---tuberculosis**[viral]{.smallcaps}**---influenza, parainfluenza, metapneumovirus, respiratory syncytial virus, adenovirus, dengue, coronavirus**[fungal]{.smallcaps}**---histoplasmosis, coccidioidomycosis**[parasitic]{.smallcaps}**---malaria, Loeffler's syndrome (migration of larval helminths such as ascaris, strongyloides, and hookworm)

### FEVER WITH RASH {#FPar56}

---see FEVER AND RASH (p. 260)

### HEMORRHAGIC FEVER {#FPar57}

**[bacterial]{.smallcaps}**---rickettsial, meningococcemia, leptospirosis**[viral]{.smallcaps}**---dengue, yellow fever, Ebola fever, Lassa fever, Marburg**[parasitic]{.smallcaps}**---malaria

### FEVER WITH SEXUAL OR BLOOD EXPOSURES {#FPar58}

---syphilis, CMV, EBV, HIV, HBV

### FEVER WITH EOSINOPHILIA {#FPar59}

---parasitic (acute hookworm, ascaris, strongyloides, acute schistosomiasis, visceral larva migrans, lymphatic filariasis, acute trichinosis)

### FEVER WITH THROMBOCYTOPENIA {#FPar60}

---malaria, typhoid fever, dengue shock syndrome, ehrlichiosis, Rocky Mountain spotted fever

### ACUTE TRAVELER'S DIARRHEA ± FEVER {#FPar61}

**[bacterial]{.smallcaps}**---Enterotoxigenic or enteroaggregative *E. coli*, *Campylobacter jejuni*, *Salmonella*, *Shigella*, *Vibrio*, *Aeromonas*, *Plesiomonas*, *C. difficile***[viral]{.smallcaps}**---Caliciviruses (Norwalk, Norwalk-like), rotaviruses, Ebola fever, enteroviruses**[parasitic]{.smallcaps}**---*Giardia lamblia*, *Cryptosporidium parvum*, *Entamoeba histolytica*, *Cyclospora cayetanensis*, *Isospora belli*, *E. polecki*, *Balantidium coli*, *Trichinella spiralis*

### CHRONIC TRAVELER'S DIARRHEA ± FEVER {#FPar62}

**[bacterial]{.smallcaps}**---Enteroaggregative or enteropathogenic *E. coli*, *C. jejuni*, *Shigella*, *Salmonella*, *Yersinia enterocolitica*, *Aeromonas*, *Plesiomonas*, *C. difficile*, *Tropheryma whippelii***[mycobacterial]{.smallcaps}**---tuberculosis, *M. avium* complex**[fungal]{.smallcaps}**---*Paracoccidioides brasiliensis*, *Histoplasma capsulatum***[parasitic]{.smallcaps}**---*G. lamblia*, *E. histolytica*, *Cryptosporidium parvum*, *C. cayetanensis*, *Trichuris trichiura*, *Strongyloides stercoralis*, Schistosomiasis, *Capillaria philippinensis*, *Fasciolopsis buski*, *Metagonimus yokogawai*, Echinostoma**[non]{.smallcaps}**-**[infectious]{.smallcaps}**---small-bowel overgrowth syndrome, disaccharidase deficiency, tropical sprue, irritable bowel syndrome, inflammatory bowel disease, cancer, laxative use, endocrinopathy, dysmotility, idiopathic

[www.phac-aspc.gc.ca/publicat/ccdr-rmtc/06vol32/acs-01/index-eng.php](http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/06vol32/acs-01/index-eng.php)

Clinical Features {#Sec26}
-----------------

### HISTORY {#FPar63}

---pattern and duration of fever, associated symptoms (cough, dyspnea, chest pain, diarrhea, abdominal pain, dysuria, urethral discharge, neck stiffness, headache), weight loss, night sweats, travel history (specific itinerary, activities and exposures including food and fresh/saltwater history, incubation period), sexual history, immunization status, antimalarial chemoprophylaxis (medications, degree of adherence), past medical history (rheumatologic disorders, malignancy), medications

### PHYSICAL {#FPar64}

---vitals (tachycardia, tachypnea, hypotension, fever, hypoxemia), oral ulcers, lymphadenopathy, nuchal rigidity, respiratory and cardiac examination (murmurs), abdominal examination (hepatosplenomegaly), skin lesions (morphology, distribution), tick bite marks, joint examination

Investigations {#Sec27}
--------------

### BASIC {#FPar65}

**[labs]{.smallcaps}**---CBCD, lytes, urea, Cr, AST, ALT, ALP, bilirubin, urinalysis**[microbiology]{.smallcaps}**---blood C&S, sputum Gram stain/AFB/C&S, urine C&S, stool C&S, O&P, C. diff toxin A/B, malaria thick and thin smear (repeat × 1 within 12--24 h if initially negative result), serologies (HIV, dengue, rickettsiae, schistosomiasis, strongyloidiasis, leptospira, HAV, HBV, HCV, Hepatitis E)**[imaging]{.smallcaps}**---CXR, US abd guided by symptoms

### SPECIAL {#FPar66}

**[lumbar puncture]{.smallcaps}**

Pre-travel Considerations {#Sec28}
-------------------------

### VACCINATIONS {#FPar67}

---standard regardless of travel (influenza, pneumococcal if age \>65, hepatitis B, MMR, DPT), developing countries (hepatitis A), specific countries (meningococcal, Japanese encephalitis, yellow fever), high-risk activity (rabies), outbreaks (cholera)

### MALARIA PROPHYLAXIS {#FPar68}

---see below

### DIARRHEA PROPHYLAXIS {#FPar69}

---ciprofloxacin and imodium if diarrhea develops

Specific Entities {#Sec29}
-----------------

### PRIORITY {#FPar70}

---focus on those illnesses that are potentially fatal or may be public health threats

### TOP TRAVEL-RELATED INFECTIONS {#FPar71}

---malaria, typhoid fever, dengue fever, diarrheal disease, respiratory infections, Lyme disease, Q fever, brucellosis

### MALARIA {#FPar72}

---the most important cause of fever in returning travelers. *P. falciparum* can be rapidly fatal and must be ruled out in all febrile travelers returning from malaria-endemic regions. It has the shortest incubation period and \>90% of affected travelers will become ill within 30 days of return**[pathophysiology]{.smallcaps}**---anopheline mosquito bite transmits sporozoites → travel to liver and invade hepatocytes → divide and form schizonts which contain merozoites (asymptomatic) → rupture after 6--16 days and release merozoites into the bloodstream → infect erythrocytes and mature from ring forms to trophozoites to mature schizonts (asexual form) over 48 (*P. vivax*, *P. ovale*, *P. falciparum*) or 72 (*P. malariae*) hours → merozoites released from erythrocytes (fever, anemia, lactic acidosis, cytokine release) and infect new red cells → few merozoites differentiate into male or female gametocytes (sexual forms) can circulate in blood until ingested by mosquito. *P. vivax* and *P. ovale* may stay dormant in the liver as hypnozoites and may cause late relapse by reactivating after many months. In contrast, *P. falciparum* and *P. malariae* have no liver stage and do not cause relapse. *P. falciparum* specifically can induce obstruction of microvascular blood flow, and may lead to organ dysfunction (e.g. cerebral malaria, renal failure, ARDS, hypoglycemia, anemia, DIC, and gastroenteritis)**[clinical features]{.smallcaps}**---*P. falciparum* is acquired mostly from sub-Saharan Africa, while *P. vivax* is mostly from Asia or Latin America. Symptoms include spiking fevers, chills, headache, back pain, cough, GI problems. Splenomegaly and thrombocytopenia without leukocytosis may be present. Cerebral malaria (*P. falciparum*) presents as altered level of consciousness or seizures and is universally fatal if untreated**[diagnosis]{.smallcaps}**---thick and thin smear (need to repeat over 48 h to rule out malaria)**[prophylaxis]{.smallcaps}**---the relative risk of contracting malaria varies by geographic region: Caribbean 4, North Africa 7, South America 8, Southeast Asia 12, Central America 38, South Asia 54, Oceania 77, and sub-Saharan Africa 208. Travelers should be advised to wear long sleeves/pants between dusk and dawn, use mosquito repellents containing 30--50% DEET, and consider permethrin-treated mosquito nets. Chloroquine may be used for travel to destinations with chloroquine-sensitive *P. falciparum* (e.g. most of Central America and parts of the Middle East). For destinations where chloroquine-resistant *P. falciparum* is present, chemoprophylaxis with atovaquone--proguanil, mefloquine, or doxycycline should be used. Give atovaquone--proguanil or doxycycline for travel to destinations with *P. falciparum* resistance to chloroquine, mefloquine, and sulfonamides (e.g. regions of Thailand, Cambodia, China, Laos, and Vietnam). Atavaquone--proguanil associated with fewest side effects. Mefloquine has ease of weekly dosing. Doxycycline is the cheapest, but requires prolonged course and causes sun sensitization. CDC 2010 risk assessment and prophylaxis recommendations are available online at<http://wwwnc.cdc.gov/travel/yellowbook/2010/chapter-2/malaria-risk-information-and-prophylaxis.aspx>**[treatments]{.smallcaps}**---artesunate has emerged as the treatment of choice for complicated malaria. Other options include quinine--doxycycline, atovaquone--proguanil, and mefloquine. Chloroquine--primaquine for non-falciparum

NEJM 2008 359:6

[www.phac-aspc.gc.ca/publicat/ccdr-rmtc/09vol35/35s1/index-eng.php](http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/09vol35/35s1/index-eng.php)

### TYPHOID FEVER {#FPar73}

**[pathophysiology]{.smallcaps}**---acquired after exposure to food or water contaminated by *Salmonella typhi***[clinical features]{.smallcaps}**---mainly in developing countries. Fever, chills, headache, myalgia, abdominal pain and constipation (uncommonly diarrhea), relative bradycardia, splenomegaly, and rose spots (faint salmon-colored macules on the abdomen and trunk). Septic symptoms from intestinal perforation may occur in second week**[diagnosis]{.smallcaps}**---blood, stool, urine, or bone marrow (highest sensitivity) culture; CBC may show leukopenia**[treatments]{.smallcaps}**---fluoroquinolones, ceftriaxone, azithromycin

### DENGUE FEVER (break-bone fever) {#FPar74}

**[pathophysiology]{.smallcaps}**---flavivirus transmitted by mosquito → flu-like illness 4--7 days later → may develop lymphadenopathy, maculopapular/petechial rash → dengue shock syndrome and dengue hemorrhagic fever if previously exposed to other serotypes**[clinical features]{.smallcaps}**---acquired mostly from tropical and subtropical areas. Fever, headache, retro-orbital pain, severe myalgia/arthralgia. Leukopenia and thrombocytopenia**[diagnosis]{.smallcaps}**---serology**[treatments]{.smallcaps}**---supportive

### EBOLA FEVER {#FPar75}

**[epidemiology]{.smallcaps}**---flavivirus possibly transmitted by fruit bats → person to person transmission occurs from direct contact with blood or bodily fluids (saliva, blood, vomit, stool or semen) of infected symptomatic patients. Incubation period is 2--21 days. 2014 outbreaks in Sierra Leon, Guinea, and Liberia**[clinical features]{.smallcaps}**---early symptoms include fever, headache, myalgia/arthralgia, vomiting, diarrhea, abdominal pain, conjunctival injection, and rash. Late symptoms include bleeding, shock, delirium and death**[diagnosis]{.smallcaps}**---high index of suspicion if patient has recently been in endemic area during an Ebola outbreak. Serology (sens 91%) and RT-PCR (sens close to 100%, spc 97%)**[treatments]{.smallcaps}**---rapid isolation. Supportive measures are the mainstay. An experimental therapy, ZMapp, consists of 3 monoclonal antibodies against Ebola viral antigens. Its efficacy has not been proven

### CHIKUNGUNYA FEVER {#FPar76}

**[pathophysiology]{.smallcaps}**---mosquito-borne viral infection acquired in Africa and Asia. Large outbreaks ongoing in Indian Ocean islands and India**[clinical features]{.smallcaps}**---fever (usually within 2--4 days of exposure) with severe joint pains involving small joints of hands, wrists, and ankles; may be prolonged. Leukopenia, thrombocytopenia, and elevated transaminases may be seen**[diagnosis]{.smallcaps}**---serology (acute and convalescent)**[treatments]{.smallcaps}**---symptomatic with NSAIDs

### RICKETTSIAL INFECTIONS (OUTSIDE OF NORTH AMERICA) {#FPar77}

**[pathophysiology]{.smallcaps}**---African tick typhus (*Rickettsia africae*), Mediterranean tick typhus (*R. conorii*), and scrub typhus (*Orientia tsutsugamushi*) are all transmitted by ticks**[clinical features]{.smallcaps}**---tick bite ± inoculation eschar with a triad of fever, headache, and myalgia. Rash may be present. Lymphadenopathy, leukopenia, and thrombocytopenia**[diagnosis]{.smallcaps}**---serology**[treatments]{.smallcaps}**---doxycycline

### RICKETTSIAL INFECTIONS (WITHIN OF NORTH AMERICA)---see FEVER AND RASH (p. 260) LEPTOSPIROSIS {#FPar78}

**[pathophysiology]{.smallcaps}**---*Leptospira interrogans*, zoonosis more common in tropical areas**[clinical features]{.smallcaps}**---history of exposure to freshwater. Fever, headache, myalgia, rash, conjunctival suffusion. May be associated with aseptic meningitis, uveitis, elevated transaminases, jaundice, proteinuria, and microscopic hematuria; fulminant syndrome with jaundice, renal failure, and hemorrhage (Weil's disease)**[diagnosis]{.smallcaps}**---serology; culture of blood, urine, and CSF**[treatments]{.smallcaps}**---doxycycline or amoxicillin for mild disease; penicillin/ampicillin or ceftriaxone/cefotaxime IV for severe disease

### BRUCELLOSIS (undulant fever, Mediterranean fever) {#FPar79}

**[pathophysiology]{.smallcaps}**---Gram-negative facultative intracellular coccobacilli**[clinical features]{.smallcaps}**---transmitted by drinking or eating infected animal products (milk), inhalation, or direct animal contact through skin wounds. Other than fever, may involve any organ system, particularly joints (sacroiliitis), GU (epididymo-orchitis), CNS (meningitis), eyes (uveitis), cardiac (endocarditis), pulmonary (pneumonitis, pleural effusion, empyema), and can cause abscesses (hepatic, splenic, thyroid, epidural). May develop into chronic hepatosplenic disease**[diagnosis]{.smallcaps}**---blood cultures, serology**[treatments]{.smallcaps}**---doxycycline plus streptomycin or rifampin

NEJM 2007 356:8

### SCHISTOSOMIASIS {#FPar80}

**[pathophysiology]{.smallcaps}**---trematode worms *S. haematobium*, *S. mansoni*, *S. intercalatum* in sub-Saharan Africa, *S. mansoni* in part of South America, *S. japonicum* in Asia, *S. mekongi* in Cambodia. Freshwater exposure → cercariae penetrate skin → larvae migrate to lung through venous circulation → migrate to heart → migrate to liver, where they mature and pair off → migrate to mesenteric venules of bowel (*S. mansoni*, *mekongi*, *japonicum*, *and intercalatum*) bladder (*S. hematobium*), where females lay eggs → excreted into feces or urine → mature to cercariae**[clinical features]{.smallcaps}**---this parasitic infection is generally seen in patients from endemic areas instead of travelers. Initial penetration of skin may cause pruritus. Acute schistosomiasis (Katayama fever) includes fever, headache, myalgias, RUQ pain, bloody diarrhea, and dyspnea. Chronic schistosomiasis with granuloma formation is due to host's immune response to schistosome eggs, leading to hepatic (cirrhosis), intestinal (diarrhea, occult blood, fibrosis) or genitourinary tract symptoms (hematuria, dysuria, calcification, fibrosis), and rarely CNS (seizures, focal deficit, transverse myelitis) involvement**[diagnosis]{.smallcaps}**---serology, schistosome eggs in feces or urine, biopsy of rectum or bladder**[treatments]{.smallcaps}**---*praziquantel* 20 mg/kg PO q8h × 2 doses (3 doses for *S. japonicum* and *mekongi*); adjunctive corticosteroids for Katyama fever

Pneumonia {#Sec30}
=========

See PNEUMONIA (p. 7)

Endocarditis {#Sec31}
============

See ENDOCARDITIS (p. 60)

Meningitis {#Sec32}
==========

NEJM 2006 354:1

Differential Diagnosis for Fever and Neurological Symptoms {#Sec33}
----------------------------------------------------------

### ★**DIMS**★ {#FPar81}

**D** **[rugs]{.smallcaps}**---neuroleptic malignant syndrome, serotonin syndrome, sympathomimetics, alcohol withdrawal**[Infectious]{.smallcaps}** **[meningitis]{.smallcaps}**---bacterial (*S. pneumoniae*, *N. meningitidis*, *H. influenzae*, *L. monocytogenes*, *Klebsiella*, *E. coli*, *Serratia*, *Pseudomonas*), viral (enterovirus, VZV, influenza, mumps, HIV), TB, fungal (*Cryptococcus*)**[encephalitis]{.smallcaps}**---HSV, West Nile, St. Louis, Equine, La Crosse**[abscess]{.smallcaps}**---bacterial**[Metabolic]{.smallcaps}**---thyroid storm**[Structural]{.smallcaps}** **[hemorrhage]{.smallcaps}**---subarachnoid, epidural, subdural, intracerebral**[cerebral infarct]{.smallcaps}[tumor]{.smallcaps}[pituitary apoplexy]{.smallcaps}[vascular]{.smallcaps}**---TTP/HUS, lupus, vasculitis, granulomatous angiitis

Pathophysiology {#Sec34}
---------------

### ASSOCIATIONS WITH SPECIFIC ORGANISMS {#FPar82}

**[age]{.smallcaps}** **0**--**4** **[weeks]{.smallcaps}**---*S. agalactiae*, *E. coli*, *Listeria monocytogenes*, *K. pneumoniae***[age]{.smallcaps}** **1**--**23** **[months]{.smallcaps}**---*S. agalactiae*, *E. coli*, *S. pneumoniae*, *H. influenzae*, *N. meningitidis***[age]{.smallcaps}** **2**--**50** **[years]{.smallcaps}**---*S. pneumoniae*, *N. meningitidis***[age]{.smallcaps}** \>**50** **[years]{.smallcaps}**---*S. pneumoniae*, *N. meningitidis*, *L. monocytogenes*, aerobic Gram-negative bacilli\***[immunocompromised]{.smallcaps}**---*Listeria*, aerobic Gram negative bacilli\***[neurosurgery]{.smallcaps}**/**[head trauma]{.smallcaps}**---*S. aureus*, *S. epidermidis*, aerobic Gram-negative bacilli\***CSF** **[shunt]{.smallcaps}**---*S. aureus*, *S. epidermidis*, aerobic Gram negative bacilli\*, diphtheroids**[basilar skull fracture]{.smallcaps}**---*S. pneumoniae*, *H. influenzae*, group A Streptococci

\*aerobic Gram-negative bacilli include *Klebsiella*, *E. coli*, *Serratia*, *and Pseudomonas*

### RISK FACTORS FOR *S*. *[PNEUMONIAE]{.smallcaps}* {#FPar83}

---pneumonia, otitis media, mastoiditis, sinusitis, endocarditis, head trauma with CSF leak, alcoholism, splenectomy

### RISK FACTORS FOR *L*. *[MONOCYTOGENES]{.smallcaps}* {#FPar84}

---extremes of age, alcoholism, malignancy, immunosuppression, diabetes, hepatic failure, renal failure, iron overload, collagen vascular disease, HIV

### COMPLICATIONS {#FPar85}

---neurologic complications include herniation, stroke, vasculitis, acute cerebral hemorrhage, and aneurysm formation of cerebral vessels, with symptoms such as seizures, hearing loss, and neuropsychological impairment. Systemic complications include septic shock, pneumonia, and ARDS

Clinical Features {#Sec35}
-----------------

### RATIONAL CLINICAL EXAMINATION SERIES: DOES THIS ADULT PATIENT HAVE ACUTE MENINGITIS? {#FPar86}

Sens (%)Spc (%)**History**Headache68Nausea and vomiting52Neck pain28**Physical**Fever87Neck stiffness80Altered mental status69Focal neurological findings21Rash13Kernig sign (patient lying supine with hip flexed \>90°. Extension of knee from this position elicits resistance or pain in lower back or posterior thigh)9100Brudzinski sign (passive neck flexion in supine patient results in flexion of knees and hips)----Jolt accentuation of headache (patient turns head horizontally at a frequency of 2--3 rotations per second. Worsening headache represents positive sign)9760**Combination of Findings**Classic triad (fever, neck stiffness, headache)46 ***UPDATE***---individual findings are not sufficiently accurate to diagnose meningitis. Absence of all 3 signs of the classic triad of fever, neck stiffness, and altered mental status is *not* sufficiently sensitive to rule out a diagnosis of meningitis. Fever and neck stiffness are the most sensitive findings of the triad. Kernig and Brudzinski signs have low sensitivity but high specificity. Jolt accentuation of headache may be a useful adjunctive maneuver for patients with fever and headache but requires further validation

JAMA 1999 282:2

The Rational Clinical Examination. McGraw-Hill, 2009

Investigations {#Sec36}
--------------

### BASIC {#FPar87}

**[labs]{.smallcaps}**---CBCD, lytes, Cr/urea, INR, PTT, AST, ALT, ALP, bilirubin, fibrinogen, urinalysis**[microbiology]{.smallcaps}**---blood C&S, sputum Gram stain/AFB/C&S, urine C&S**[imaging]{.smallcaps}**---CXR, head CT (see below)**[lumbar puncture]{.smallcaps}**---(1) cell count and differential; (2) Gram stain, C&S and AFB; (3) cell count and differential; (4) protein, glucose, lactate; (5) PCR for HSV, VZV, enteroviruses; (6) cytology

Diagnostic and Prognostic Issues {#Sec37}
--------------------------------

### LUMBAR PUNCTURE {#FPar88}

---suspect bacterial infection if high neutrophils, low glucose, high protein, positive culture. Suspect viral infection if high lymphocytes, *normal* glucose, and normal/high protein (**NEJM 2006 355**:**e12**)**[opening pressure]{.smallcaps}**---normal is 60--250 mmH~2~O. Causes of elevated opening pressure include meningitis, pseudotumor cerebri, intracranial hemorrhage, tumors, and idiopathic**[cell count and differential]{.smallcaps}**---normal WBC is \<5/mm^3^. This can increase to 1000--5000/mm^3^ for bacterial meningitis (neutrophils mainly) and 50--1000/mm^3^ for viral meningitis (lymphocyte predominant). Other causes include seizure, intracerebral hemorrhage, tumor, and "traumatic tap" (correct by +1 WBC for every 500--1000 RBCs)**[xanthochromia]{.smallcaps}**---lysed RBCs. Present in \>90% of patients within 12 h of subarachnoid hemorrhage onset**[gram stain]{.smallcaps}**---sensitivity is 60--80% in untreated bacterial meningitis and 40--60% in partially treated cases**[culture]{.smallcaps}**---gold standard with sensitivity of 70--85% in untreated bacterial meningitis and 50% in partially treated cases. Viral, TB, and fungal cultures may be done as well**[protein]{.smallcaps}**---normal is 0.18--0.58 g/L. Significantly elevated in bacterial meningitis and obstruction, variably elevated in fungal and TB infections, and only sometimes elevated in viral infections. Other causes include tumors, intracranial hemorrhages, multiple sclerosis, and Guillain--Barre syndrome**[glucose]{.smallcaps}**---normal is 2/3 of serum level, up to 16.7 mM \[300 mg/dL\]. Significantly lower in bacterial meningitis, mildly lower in fungal and TB infections, and usually normal in viral infections

### RATIONAL CLINICAL EXAMINATION SERIES: HOW DO I PERFORM A LUMBAR PUNCTURE AND ANALYZE THE RESULTS TO DIAGNOSE BACTERIAL MENINGITIS? {#FPar89}

**TECHNIQUE**---"use of an **atraumatic needle** compared with a standard needle and use of a **26**-**gauge** standard needle compared with a 22-gauge standard needle have been shown to be associated with reduced risk of headache after lumbar puncture. **Reinsertion of the stylet** before needle removal should occur (ARR 11%). **Patients do not require bed rest** after the procedure" LR+**CSF analysis**CSF blood glucose ratio ≤ 0.418CSF glucose \>2.2 mmol/L \[\>40 mg/dL\]23CSF WBC ≥ 500/μL15CSF lactate ≥ 3.5 mmol/L \[≥32 mg/dL\]21

JAMA 2006 296:16

### CT HEAD {#FPar90}

---indicated before lumbar puncture only if age \>60, immunocompromised, history of CNS disease, seizures within 1 week, focal neurological abnormalities, papilloedema, obtunded or unconscious, inability to answer two questions correctly, or inability to follow two commands correctly

NEJM 2001 345:24

### PROGNOSIS {#FPar91}

---mortality rate is 19--26% for *S. pneumoniae* meningitis and 3--13% for *N. meningitidis* meningitis. Factors conferring poor prognosis include systemic compromise, ↓ level of consciousness, and *S. pneumonia*

NEJM 2004 351:18

Management {#Sec38}
----------

### ACUTE {#FPar92}

---ABC, O~2~, IV, intubation. Droplet precautions for suspect *N. meningitidis* infection

### EMPIRIC ANTIBIOTICS {#FPar93}

---**steroid** if acute bacterial meningitis and *15*--*20 min before* first dose of antibiotics (*dexamethasone* 0.15 mg/kg or 10 mg IV q6h × 4 days). ***Cefotaxime*** 2 g IV q6h or ***ceftriaxone*** 2 g IV q12h. Add ***vancomycin*** 500--750 mg IV q6h if concerned about penicillin-resistant Pneumococci. Add ***ampicillin*** 2 g IV q4h if age \>50 for *Listeria* coverage. If neurosurgery/trauma, CSF shunt, or basilar skull fracture, give ***ceftazidime*** 2 g IV q8h plus **vancomycin**. If HSV encephalitis, give ***acyclovir*** 10 mg/kg IV q8h

### SPECIFIC ANTIBIOTICS {#FPar94}

---***S. pneumoniae*** (penicillin G or ampicillin if MIC \<0.1 μg/mL, ceftriaxone or cefotaxime ± vancomycin × 10--14 days if MIC \>1.0 μg/mL), ***N. meningitidis*** (ceftriaxone, penicillin G or ampicillin × 7 days), ***L. monocytogenes*** (ampicillin or penicillin G, plus gentamicin × 21 days), ***H. influenzae*** (ampicillin, ceftriaxone, or cefotaxime × 7 days), **Enterobacteriaceae** (ceftriaxone or cefotaxime × 7 days)

Specific Entities {#Sec39}
-----------------

### CHRONIC MENINGITIS {#FPar95}

(\>4 weeks symptoms and persistent CSF abnormalities)---consider TB, fungal infections, neurosarcoidosis, lymphoma, and leptomeningeal carcinomatosis

### RECURRENT MENINGITIS {#FPar96}

---**congenital predisposition** (myelomeningocele, dermal sinus), **acquired** (trauma, tumor, shunt), **immunologic defects** (complement defects, antibody defects, splenectomy)

### HSV ENCEPHALITIS {#FPar97}

**[pathophysiology]{.smallcaps}**---usually infects the temporal lobe → subacute illness with fever, focal neurologic abnormalities, aphasia, mental status changes, and seizures. May have long-term sequelae**[diagnosis]{.smallcaps}**---lumbar puncture (mild lymphocytic pleocytosis \<500 cells/μL, erythrocytes, xanthochromia, ↑ protein, normal glucose, PCR for HSV1 and HSV2), MRI (hyperintense lesion in the inferior medial temporal lobe, often extending into the insula)**[treatments]{.smallcaps}**---*acyclovir* 10 mg/kg/dose q8h × 14--21 days

### WEST NILE VIRUS ENCEPHALITIS {#FPar98}

**[pathophysiology]{.smallcaps}**---flavivirus West Nile virus transmitted by mosquitoes between late spring and early autumn**[clinical features]{.smallcaps}**---wide spectrum from asymptomatic (30%) to severe neurologic disorder (0.5%). Fever, erythematous rash, meningitis, encephalitis, and flaccid paralysis. Risk of progression to severe neurological disease about 1/150, highest in the elderly**[diagnosis]{.smallcaps}**---lumbar puncture (viral picture, PCR for West Nile virus), IgM antibody to West Nile virus in serum or cerebrospinal fluid (samples from the acute and convalescent phases, submitted at least 2 weeks apart)**[treatments]{.smallcaps}**---supportive. Prevention is key (insect repellent, proper clothing)

### Related Topics {#FPar99}

Delirium (p. 432)

Infection Control (p. 304)

Urinary Tract Infections and Sexually Transmitted Infections {#Sec40}
============================================================

Urol Clin N Am 2008;35:1;

[www.phac-aspc.gc.ca/std-mts/sti-its/guide-lignesdir-eng.php](http://www.phac-aspc.gc.ca/std-mts/sti-its/guide-lignesdir-eng.php)

CID 2011:52(5)

Differential Diagnosis of Dysuria {#Sec41}
---------------------------------

### ★SUV★ {#FPar100}

**[Sexually transmitted diseases]{.smallcaps}**---*Chlamydia trachomatis*, *Neisseria gonorrhoeae*, HSV**[Urinary tract infections]{.smallcaps}** (urethritis, cystitis, pyelonephritis, perinephric abscess)---**bacterial** (★**KEEPS**★ ***K*** *lebsiella*, ***E***. *coli*, ***E*** *nterococci*, ***P*** *roteus*, ***S*** *taphylococcus saprophyticus*)**[VAGINAL INFECTIONS]{.smallcaps}**---*Candida albicans*, Trichomonas, bacterial vaginosis

Pathophysiology of Urinary Tract Infections {#Sec42}
-------------------------------------------

### COMPLICATED UTI {#FPar101}

---presence of functional or anatomic abnormality of the urinary tract (polycystic kidney disease, nephrolithiasis, neurogenic bladder, diabetes, immunosuppression, pregnancy, indwelling urinary catheter, recent urinary tract instrumentation)

### UNCOMPLICATED UTI {#FPar102}

---absence of risk factors above. In women, uncomplicated UTIs are usually treated for 3 days (or 5--7 days with nitrofurantoin)

### PYELONEPHRITIS {#FPar103}

---usually 18--40-year-old women, fever, costovertebral angle tenderness, blood and urine cultures indicated. Challenges differentiating between cystitis and pyelonephritis

### RISK FACTORS FOR UTI {#FPar104}

**[young women]{.smallcaps}**---frequent or recent sexual activity**[elderly women]{.smallcaps}**---age, estrogen deficiency, incontinence, diabetes, cystoceles, previous GU surgery

### PATHOPHYSIOLOGY OF CATHETER-ASSOCIATED BACTERIURIA {#FPar105}

---bacteria establish biofilm in or on catheter and enter bladder intra- or extraluminally. Common organisms include *E. coli* and enterococci. Responsible for 80% of urosepsis. Risk factors include duration of catheterization, errors in catheter care, diabetes mellitus, and female sex

Clinical Features of Urinary Tract Infections {#Sec43}
---------------------------------------------

### RATIONAL CLINICAL EXAMINATION SERIES: DOES THIS WOMAN HAVE ACUTE UTI? {#FPar106}

LR+LR--**History**Dysuria1.50.5Frequency1.80.6Hematuria2.00.9Fever1.60.9Flank pain1.10.8Lower abdominal pain1.10.9Vaginal discharge0.33.1Vaginal irritation0.22.7Back pain1.60.8**Physical**Vaginal discharge0.71.1CVA tenderness1.70.9**Urine dipstick**Leukocyte esterase or nitrite positive4.20.3 **APPROACH**---"four symptoms (dysuria, frequency, hematuria, back pain) and one sign (CVA tenderness) increased the probability of UTI and may effectively rule in if all present. However, no combinations reliably rule out UTI. Urinalysis is moderately powerful and should be considered in women with appropriate urinary tract symptoms. If the dipstick leukocyte esterase or nitrite is positive, the probability of UTI is high, especially when combined with other positive findings from the history and physical. If dipstick is negative but probability of disease is still relatively high, a urine culture should be considered to rule out infection"

JAMA 2002 287:20

The Rational Clinical Examination. McGraw-Hill, 2009

Investigations for Urinary Tract Infections {#Sec44}
-------------------------------------------

### BASIC {#FPar107}

**[labs]{.smallcaps}**---CBCD, lytes, Cr/urea, urinalysis**[microbiology]{.smallcaps}**---urine C&S

Diagnostic Issues for Urinary Tract Infections {#Sec45}
----------------------------------------------

### NUMBER OF BACTERIA {#FPar108}

---significant bacteria (\>10^5^/mL) in clean catch suggests UTI (sens 50%). If using lower threshold to \>10^3^/mL for women with symptoms, sensitivity increases and specificity only decreases slightly

### URINALYSIS {#FPar109}

---nitrite or leukocyte esterase (sens 75%, spc 82%), pyuria (sens 95%, spc 71%), bacteria (sens 40--70%, spc 85--95%). Not necessary if symptomatic uncomplicated UTI

### URINE CULTURE {#FPar110}

---not always needed if symptomatic and biochemical evidence (i.e. leukocyte esterase) of uncomplicated UTI (see Clinical Features). However, antimicrobial resistance is increasing, so culture and sensitivity may become more important

Management of Urinary Tract Infections {#Sec46}
--------------------------------------

### UNCOMPLICATED UTI IN WOMEN {#FPar111}

---*trimethoprim*--*sulfamethoxazole* (DS-160/800 mg) 1 tab PO BID × 3 days, *ciprofloxacin* 250--500 mg PO BID × 3 days, *levofloxacin* 250--500 mg PO daily × 3 days, *nitrofurantoin macrocrystals* 50 mg PO QID × 5--7 days, *nitrofurantoin monohydrate macrocrystals* 100 mg PO BID × 5--7 days, *amoxicillin*--*clavulanate* 500 mg PO BID × 7 days, *fosfomycin trometamol* 3 g PO × 1 dose

### COMPLICATED UTI {#FPar112}

---treatment duration 7--14 days

### RECURRENT UTI {#FPar113}

(consider below measures if \>3--4 episode of UTI/year)---**daily low**-**dose prophylaxis** (*trimethoprim*--*sulfamethoxazole DS* ½ tab PO qhs × 6 months, *nitrofurantoin* 50 mg or macrocrystals 100 mg PO qhs × 6 months), **postcoital prophylaxis** (*trimethoprim*--*sulfamethoxazole* DS ½-1 tab PO post-coital, *nitrofurantoin* 50 mg PO or *macrocrystals* 100 mg PO post-coital), **patient**-**initiated treatment** (start standard dose of antibiotics with onset of UTI symptoms)

### SYMPTOM CONTROL {#FPar114}

---***phenazopyridine*** 100--200 mg PO TID × 2 days

### ACUTE UNCOMPLICATED PYELONEPHRITIS {#FPar115}

---treat empircally with oral fluoroquinolones × 7 d (*ciprofloxacin* 500 mg PO BID or *levofloxacin* 750 mg PO daily). If isolate susceptible, may treat with trimethoprim--sulfamethoxazole, amoxicillin, or amoxicillin--clavulanate × 14 d. Most otherwise healthy, non-pregnant women with pyelonephritis can be treated on an outpatient basis. Otherwise, treat with IV antibiotics, at least initially (aminoglycoside ± ampicillin, third generation cephalosporin, or carbapenem)

### CATHETER-ASSOCIATED BACTERIURIA {#FPar116}

---remove or replace catheter and initiate antibiotics for symptomatic infection; switch to intermittent catheterization

### PREGNANCY AND UTI {#FPar117}

---urinalysis for all pregnant women at 16 weeks. Treat all bacteriuria with amoxicillin or nitrofurantoin × 3--7 days even if asymptomatic as there is a 20--40% risk of pyelonephritis. Avoid fluoroquinolones

Vaginitis {#Sec47}
---------

### CANDIDA {#FPar118}

---vulvovaginitis with cheesy vaginal discharge, intense itch. Diagnosis by microscopy with 10% KOH showing hyphae and budding yeast, pH 4--4.5 (normal). Treat with vaginal antifungal cream (3--14 days) or *fluconazole* 150 mg PO × 1 dose

### TRICHOMONIASIS {#FPar119}

---profuse purulent greenish vaginal discharge, strawberry cervix. Diagnosis by microscopy showing motile trichomonads, pH 5--6. Treat with oral *metronidazole* 2 g as a single dose (treatment of sexual partners indicated)

### BACTERIAL VAGINOSIS {#FPar120}

---gray, fishy-smelling vaginal discharge. Diagnosis made by amine odor when KOH added to the discharge, pH \>4.5 and clue cells (vaginal epithelial cells coated with bacteria) seen on microscopy. Treat if symptomatic or pregnant with metronidazole or clindamycin, orally or vaginally

Sexually Transmitted Infections (STI) {#Sec48}
-------------------------------------

### URETHRITIS IN MEN/CERVICITIS IN WOMEN {#FPar121}

**[pathophysiology]{.smallcaps}**---*N. gonorrhea*, *Chlamydia trachomatis*, and other non-gonococcal (*Ureaplasma urealyticum*, *Mycoplasma genitalium*, *Trichomonas vaginalis*, HSV)**[diagnosis]{.smallcaps}**---Gram stain of discharge, urine for chlamydia/gonorrhea (nucleic acid amplification test, NAAT) or urethral/cervical swab for gonorrhea culture; offer syphilis and HIV testing**[treatments]{.smallcaps}**---anti-gonococcal (*cefixime* 400 mg PO × 1 or *ceftriaxone* 125 mg IM × 1 [plus]{.ul} azithromycin 1 g PO × 1), anti-chlamydial (*azithromycin* 1 g PO × 1, or *doxycycline* 100 mg PO BID × 7 days). If gonorrhea identified, empirically treat for both gonococcus and chlamydia since dual infection is common. Dual therapy is recommended for gonorrhea due to increasing incidence of resistance to third generation cephalosporins. Trace and treat all partners within the last 60 days

### SYPHILIS {#FPar122}

**[pathophysiology]{.smallcaps}**---*Treponema pallidum* infection. Risk factors include men who have sex with men (MSM), sex trade, HIV infection**[primary syphilis]{.smallcaps}**---presents as chancre (painless, indurated, non-purulent ulcer) within 3--90 days**[secondary syphilis]{.smallcaps}**---develops within 2 weeks to 6 months, with symptoms such as fever, maculopapular rash, mucocutaneous lesions, alopecia, lymphadenopathy, meningitis, uveitis, and cranial neuritis**[tertiary syphilis]{.smallcaps}**---develops after year(s) and may involve the heart (aortitis), eyes (iritis, Argyll Robertson pupil), bones/soft tissues (gummas), and neurologic system (general paresis, a rapidly progressive dementia with psychotic features and tabes dorsalis which affects posterior columns of the spinal cord and the dorsal roots, leading to pain episodes, decreased vibration and proprioception, absent reflexes, and bowel/bladder dysfunction)**[diagnosis]{.smallcaps}**---first-line diagnostic test of choice for a primary syphilitic chancre should be either DFA or PCR, if available. Otherwise, treponemal serologies are more sensitive and become positive earlier than non-treponemal serologies and would be preferred if primary syphilis is a consideration

Diagnostic MethodTest(s)UtilityDirect visualizationDark field microscopyTraditional but availability is limitedVisualization with fluorescent AbDFADiagnosis of 1 ° syphilisSensitive/specificMolecular testingPCRDiagnosis of 1 ° syphilis. Most sensitive/specific but not readily availableTreponemal serology (presence of Ab against TP)FTA-ABSDiagnosis of syphilisTPPAMHA-TPTP-EIAINNO-LIASensitive; however, does not differentiate venereal from non-venereal treponematosisNon-treponemal serology (presence of Ab against cardiolipin/lecithin)VDRLScreeningRPRRPR titer helpful in staging, check for reinfection, treatment monitoringAbbreviations: *DFA* direct fluorescent antibody, *EIA* enzyme immunoassay, *FTA-ABS* fluorescent treponemal antibody-absorption, *MHA-TP* microhemagglutination assay for antibody to TP, *PCR* polymerase chain reaction, *RPR* rapid plasma reagin test, *TP* treponema pallidum, *TPPA* TP particle agglutination assay, *VDRL* Venereal Disease Research Laboratory, *INNO-LIA* line immunoassay **[treatments]{.smallcaps}**---for primary, secondary and early latent (\<1 year) syphilis, *benzathine penicillin G* 2.4 M units IM × 1 (preferred) or *doxycycline* 100 mg PO BID × 2 weeks. For late latent (\>1 year) syphilis, gummatous and cardiovascular syphilis, *benzathine penicillin G* 2.4 M units IM q7days × 3 weeks. For neurosyphilis or syphilitic eye disease, give *benzathine penicillin G* 3--4 M units q4h IV × 10--14 days. Follow-up is essential. Treatment failure is defined as persistent symptoms or failure of serologic test to decline by 4 fold within 6 months

### PELVIC INFLAMMATORY DISEASE {#FPar123}

**[pathophysiology]{.smallcaps}**---includes endometritis, tubo-ovarian abscess, salpingitis, and pelvic peritonitis. Most commonly due to *N. gonorrhoeae*, *C. trachomatis*, *M. hominis*, *U. urealyticum*; may involve endogenous (gut) organisms including anaerobes. Complications include infertility, ectopic pregnancy, and chronic pelvic pain**[clinical features]{.smallcaps}**---lower abdominal pain, abnormal vaginal bleeding/discharge, and dyspareunia may be mild and non-specific. Findings include lower abdominal tenderness, adnexal tenderness, and cervical motion tenderness**[diagnosis]{.smallcaps}**---high index of clinical suspicion. Cervical swab and urine NAAT for Chlamydia and gonorrhea. Ultrasound. Pregnancy test**[treatments]{.smallcaps}**---**outpatients** (*ceftriaxone* 250 mg IM × 1 and *doxycycline* 100 mg PO BID × 14 days, or *levofloxacin* 500 mg PO daily × 14 days); add *metronidazole* 500 mg PO BID × 14 days if there are risk factors for anaerobic pathogens. **Inpatients** (*doxycycline* 100 mg PO q12h and *cefoxitin* 2 g IV q6h × 14 days, or *clindamycin* 900 mg IV q8h and *gentamicin* 1.5 mg/kg IV q8h × 14 days)

<http://www.phac-aspc.gc.ca/std-mts/sti-its/cgsti-ldcits/index-eng.php>

Soft Tissue Infections {#Sec49}
======================

NEJM 2007 357:4; IDSA Guidelines 2014

Differential Diagnosis {#Sec50}
----------------------

### DISCRETE LOCALIZED CUTANEOUS INFECTIONS {#FPar124}

---**superficial** (impetigo, folliculitis, furunculosis), **deep** (carbuncles, subcutaneous abscesses)

### SPREADING DIFFUSE CUTANEOUS INFECTIONS {#FPar125}

(involves deeper dermis and subcutaneous tissues)---erysipelas, cellulitis

### DEEP SOFT TISSUE INFECTIONS {#FPar126}

---necrotizing fasciitis (polymicrobial, *S. pyogenes*), gas gangrene (*C. perfringens*)

Pathophysiology {#Sec51}
---------------

### RISK FACTORS FOR CELLULITIS {#FPar127}

**[compromised skin]{.smallcaps}**---trauma, IDU, psoriasis, eczema, fungal disease (especially tinea pedis)**[compromised sensory]{.smallcaps}**/**[proprioceptive nerves]{.smallcaps}**---diabetic neuropathy**[compromised blood]{.smallcaps}**/**[lymphatic vessels]{.smallcaps}**---diabetes, malignancy, lymphatic or venous insufficiency, venectomy, radiation, prior cellulitis

### CELLULITIS {#FPar128}

---acute spreading infection involving the dermis and subcutaneous tissue, mostly caused by Staphylococci and group A S*treptococcus*. It usually presents as a swollen, erythematous plaque with illdefined border

### ERYSIPELAS {#FPar129}

---superficial cellulitis involving the upper dermis and lymphatics, mostly caused by group A *Streptococcus*. It usually presents as a raised, erythematous plaque with well-demarcated border. It occurs more commonly in infants and elderly

### RISK FACTORS FOR SKIN AND SOFT TISSUE INFECTIONS DUE TO MRSA/CA-MRSA {#FPar130}

---previous MRSA infection, hospitalization, or household contacts of known MRSA; street involved/shelters/incarceration, injection drug use, athletes, children/day care

### COMMON PATHOGENS CAUSING CELLULITIS {#FPar131}

**[most common]{.smallcaps}**---*S. pyogenes* (β-hemolytic group A *Streptococcus*), *S. aureus*, other β-hemolytic streptococci (B, C, G, and F)**[surgical wound]{.smallcaps}**---*S. aureus*, *S. pyogenes***[human bite]{.smallcaps}**---oral anaerobes, *Eikenella corrodens***[animal bite]{.smallcaps}**---*Pasteurella multocida*, *Capnocytophaga canimorsus***[tick bite]{.smallcaps}**---*Borrelia burgdorferi*, Tularemia**[freshwater]{.smallcaps}**---*Aeromonas hydrophila***[seawater]{.smallcaps}**---*Vibrio vulnificus***[fish exposure]{.smallcaps}**---*Erysipelothrix rhusiopathiae*, *Streptococcus iniae***[hot tub]{.smallcaps}**---*Pseudomonas aeruginosa* folliculitis

### RATIONAL CLINICAL EXAMINATION SERIES: DOES THIS PATIENT HAVE AN INFECTION OF A CHRONIC WOUND? {#FPar132}

LR+LR--Increasing pain11--200.64--0.88Foul odour1.5--3.10.73--0.92Discoloured granulation tissue1.4--1.90.64--0.85Erythema1.4--1.70.66--0.88Edema0.87--2.30.51--1.0Heat0.80--1.10.98--1.0Serous exudate1.1--1.90.57--0.62Purulent exudate0.50--0.741.1--1.3Delayed healing1.0--2.30.29--0.96IDSA criteria (purulent exudate or ≥2 of pain, erythema, heat, or edema)0.961.0 **APPROACH**---increasing pain is the most useful clinical feature that increases the likelihood of chronic wound infection. However, classic signs of wound infection (e.g. purulent exudate, erythema, heat, edema) used in isolation are not helpful in diagnosing chronic wound infection

JAMA 2012 307:6

Investigations {#Sec52}
--------------

### BASIC {#FPar133}

**[labs]{.smallcaps}**---CBCD, lytes, urea, Cr, lactate (if suspicion of necrotizing fasciitis)**[microbiology]{.smallcaps}**---swab of portal of entry or any open draining wound for Gram stain and C&S, blood C&S (indicated only if systemic symptoms)

Management {#Sec53}
----------

### TREAT UNDERLYING CAUSE {#FPar134}

---**incision and drainage of abscesses. Elevation** of affected area if possible, compression and skin hydration. **Antibiotics for mild cellulitis** (*cephalexin* 500 mg PO QID, *dicloxacillin* 500 mg PO QID, or *clindamycin* 150--300 mg PO QID × 5--14 days); for **systemic toxicity or severe cellulitis** (*cefazolin* 1--2 g IV q8h, *ceftriaxone* 1 g IV q24h, *nafcillin* 1--2 g IV q4--6 h × 7--14 days). For MRSA associated skin infections, consider *vancomycin* 1--2 g IV q12h, *trimethoprim*/*sulfamethoxazole* 1 DS tab PO BID, *daptomycin* 4--6 mg/kg IV daily, *tigecycline* 100 mg loading dose, then 50 mg IV q12h, *doxycycline* 100 mg PO BID, *linezolid* 600 mg PO/IV q12h. **For mild erysipelas**, consider *penicillin* 500 mg PO QID or *amoxicillin* 500 mg PO TID. For **severe erysipelas** with fevers and **chills**, consider *ceftriaxone* 1 g IV q24h or *cefazolin* 1--2 g IV q8h × 5--14 days

Specific Entities {#Sec54}
-----------------

### NECROTIZING FASCIITIS {#FPar135}

**[types]{.smallcaps}**---**type 1** (polymicrobial infections including Enterococci, *E. coli*, non-group A *Streptococcus*, *Klebsiella*, anaerobes. Mixed infections occurring postoperatively or in those with diabetes or peripheral vascular disease, e.g. Fournier's gangrene of perineum in diabetics), **type 2** (monomicrobial *Streptococcus pyogenes* "Group A strep"; rarely, CA-MRSA. May occur at any age and in healthy hosts following minor trauma, penetrating injury, laceration, varicella, IDU, or childbirth)**[pathophysiology]{.smallcaps}** (**type 1**)---inoculation of ischemic or devitalized tissue → host immune system and antibiotics relatively ineffective → rapid spreading of infection to surrounding tissue → late signs include fever, crepitus, shock → complications include compartment syndrome, acute renal failure, sepsis. May be limb or life-threatening. May develop over a few hours**[associations]{.smallcaps}**---host (age \>50, cancer, alcoholism, immunocompromised, malnutrition, obesity), compromised skin (burns, trauma, postoperative infection), compromised blood vessels (peripheral vascular disease, diabetes)**[clinical features]{.smallcaps}**---typically happens over body areas with limited fibrous tissue (trunk, extremities). Pain disproportionate to physical findings. Gangrenous skin changes, bullae, tense edema, and crepitus may be seen as late signs**[diagnosis]{.smallcaps}**---high index of suspicion (pain \>\> physical findings). Plain X-ray to check for gas with type 1 necrotizing fasciitis. CT or MRI maybe useful. Early deep incisional biopsy is gold standard**[treatments]{.smallcaps}**---urgent **surgical debridement** of all necrotic tissue. Consider **IVIG** if significant hypotension in Group A S*treptococcus* necrotizing fasciitis. **Polymicrobial** *piperacillin*--*tazobactam* 4.5 g IV q8h plus *vancomycin* 1 g IV q12h, **Streptococcus** (*penicillin G* 4 MU IV q4h plus *clindamycin* 600--900 mg IV q8h)

Osteomyelitis {#Sec55}
=============

Causes {#Sec56}
------

### HEMATOGENOUS {#FPar136}

(monomicrobial)---*S. aureus*, coagulase-negative staphylococci, Gram-negative bacilli (*P. aeruginosa*, *Serratia*, *E. coli*), TB, fungi

### CONTIGUOUS SPREAD FROM SOFT TISSUE OR JOINTS {#FPar137}

(polymicrobial)---*S. aureus*, coagulase negative Staphylococci, *S. pyogenes*, *Enterococcus*, Gram-negative bacilli, anaerobes

### CONTIGUOUS SPREAD WITH GENERALIZED VASCULAR INSUFFICIENCY {#FPar138}

(polymicrobial)---*S. aureus*, *Streptococcus*, *Enterococcus*, *Proteus mirabilis*, *P. aeruginosa*, anaerobes

### DIRECT INOCULATION THROUGH TRAUMA OR SURGERY {#FPar139}

(monomicrobial or polymicrobial)---may involve skin or environmental commensal organisms

Pathophysiology {#Sec57}
---------------

### ROUTE OF INFECTION {#FPar140}

**[hematogenous]{.smallcaps}**---mainly central (vertebrae, sternoclavicular, sacroiliac) and sometimes long bones (femur, tibia, humerus)**[contiguous spread from soft tissue infections]{.smallcaps}**---trauma, surgery, orthopedic prosthesis, decubitus ulcer**[contiguous spread from soft tissue infections with generalized vascular insufficiency]{.smallcaps}**---ischemic ulcers, diabetic ulcers

### RISK FACTORS FOR OSTEOMYELITIS {#FPar141}

**[systemic]{.smallcaps}**---diabetes, sickle cell disease (Salmonella)**[local]{.smallcaps}**---vascular compromise (arterial insufficiency, neuropathy venous stasis), orthopedic surgery

Clinical Features {#Sec58}
-----------------

### DIABETIC FOOT ULCER {#FPar142}

---either probing of bone or ulcer area above 2 cm^2^ is associated with \~90% chance of having underlying osteomyelitis (sens 66%, spc 85%, PPV 89%, NPV 56%). Further noninvasive testing is unlikely to improve accuracy of diagnosis

### RATIONAL CLINICAL EXAMINATION SERIES: DOES THIS PATIENT WITH DIABETES HAVE OSTEOMYELITIS OF THE LOWER EXTREMITY? {#FPar143}

**Wagner grading scale** **0**---no open lesions; may have evidence of healed lesions or deformities**1**---superficial ulcer**2**---deeper ulcer to tendon, bone, or joint capsule**3**---deeper tissues involved, with abscess, osteomyelitis, or tendinitis**4**---localized gangrene of toe or forefoot**5**---gangrene of foot (partial or total) LR+LR−**Clinical gestalt**Clinical judgment9.20.70Wagner grade \>25.50.54**Physical**Bone exposure9.20.70Positive probe to bone finding6.40.39Ulcer area \>2 cm^2^7.20.48Ulcer inflammation1.50.84**Laboratory**ESR ≥ 70 mm/h110.34Swab culture11Abnormal plain radiograph2.30.63Abnormal MRI3.80.14 **APPROACH**---"an ulcer area \>2 cm^2^, a positive probe-to-bone test result, an ESR ≥70 mm/h, and an abnormal plain radiograph are helpful in diagnosing the presence of lower extremity osteomyelitis in patients with diabetes. A negative MRI result makes the diagnosis much less likely when all of these findings are absent. No single historical feature or physical examination reliably excludes osteomyelitis. The diagnostic utility of a combination of findings is unknown. The gold standard for diagnosis is bone biopsy"

JAMA 2008 299:7

### SYMPTOMS {#FPar144}

**[acute osteomyelitis]{.smallcaps}** (\<2 weeks)---typically associated with bone pain, tenderness, warmth, swelling, febrile, and chills. Hip, vertebrae, and pelvis tend to manifest few signs and symptoms**[subacute osteomyelitis]{.smallcaps}** (weeks to few months)---longer duration of above symptoms, but less severe. Over time, draining sinus tracts, deformity, instability, and vascular/neurologic changes may develop**[chronic osteomyelitis]{.smallcaps}** (\>few months)---similar to subacute osteomyelitis

Investigations {#Sec59}
--------------

### BASIC {#FPar145}

**[labs]{.smallcaps}**---CBCD, ESR (monitor disease progress if elevated), urinalysis**[microbiology]{.smallcaps}**---blood C&S, urine C&S**[imaging]{.smallcaps}**---plain films (specific but insensitive), three-phase bone scan (sensitive), CT, MRI (most sensitive and specific, particularly spine and diabetic foot), indium-labeled WBC scan (specific), US, bone marrow scan, dual tracer scan

### SPECIAL {#FPar146}

**[ulcer probing]{.smallcaps}[bone biopsy]{.smallcaps}**---C&S, AFB, TB culture, fungal culture, histology; generally required for vertebral osteomyelitis (CT-guided biopsy can provide microbiological diagnosis to guide therapy)**[ankle brachial index]{.smallcaps}**---ischemic ulcers suspected

Diagnostic Issues {#Sec60}
-----------------

### PLAIN FILMS {#FPar147}

---soft tissue swelling and gas, cortical destruction, periosteal new bone formation, foreign bodies, deformities, fractures, and soft tissue gas. Usually the first imaging to investigate for osteomyelitis. However, may not detect changes until after 2--3 weeks of infection. May help make diagnosis of osteomyelitis but never excludes it (sens 61%, spc 72%, PPV 80% for diabetic foot osteomyelitis)

### BONE SCAN {#FPar148}

---more sensitive but less specific than plain films (sens 70--100%, spc 36% for diabetic foot osteomyelitis). Useful for ruling out osteomyelitis, but cannot make the diagnosis

### INDIUM-LABELED LEUKOCYTE SCAN {#FPar149}

---better sensitivity and specificity (but still poor) than bone scans in diabetic foot. Since WBC accumulates in the marrow, the scan is less sensitive in areas with red marrow (vertebrae, pelvis). Excellent for fracture nonunion osteomyelitis (sens 91%, spc 97%)

### MRI {#FPar150}

---provides great anatomic details, more sensitive and specific than bone scan. Imaging of choice for specific body sites (vertebrae, diabetic foot)

### ULTRASOUND {#FPar151}

---fluid collection adjacent to the bone without intervening soft tissue, elevation of the periosteum by \>2 mm, and thickening of the periosteum. Sensitivity and specificity uncertain

### BONE BIOPSY {#FPar152}

---gold standard for osteomyelitis and generally required in vertebral osteomyelitis. Positive blood cultures and corresponding radiologic findings may support diagnosis and sometimes replace bone biopsy. Consider holding off antibiotic therapy if not life-threatening infection to facilitate identification of organisms. Organisms from superficial skin swabs have little correlation with the actual organisms growing inside the bone, except for *S. aureus*

### Related Topic {#FPar153}

Diabetes Mellitus (p. 381)

Management {#Sec61}
----------

### HEMATOGENOUS {#FPar154}

---for vertebral osteomyelitis, need blood and bone cultures, then start empiric antibiotics with *cloxacillin* 2 g IV q4--6 h or *cefazolin* 2 g IV q8h. Consider *vancomycin* 15 mg/kg IV q12h if high local MRSA rates. Once organism identified, treat with specific antibiotic (total 6--12 weeks of antibiotics guided by susceptibility from time of biopsy or definitive surgery, with at least 2 weeks of IV therapy). If failed therapy, consider bone/soft tissue debridement and another 4--6 weeks of antibiotics after definitive surgery

### CONTIGUOUS SPREAD WITHOUT VASCULAR INSUFFICIENCY {#FPar155}

---after orthopedic surgery and specimen collection, start *vancomycin* 15 mg/kg IV q12h. For sternal osteomyelitis, give *vancomycin* 15 mg/kg IV q12h, then switch to specific antibiotics (total 6 weeks of antibiotics from time of definitive surgery, usually intravenous for the duration)

### CONTIGUOUS SPREAD WITH VASCULAR INSUFFICIENCY {#FPar156}

---polymicrobial. Base therapy on bone culture, empirical coverage should include anaerobes (e.g. carbapenems, piperacillin--tazobactam)

Specific Entities {#Sec62}
-----------------

### VERTEBRAL OSTEOMYELITIS {#FPar157}

**[pathophysiology]{.smallcaps}**---usually results from disc-space seeding through hematogenous dissemination, seeding from urinary tract, trauma, extension of infection from adjacent structures, or as a complication of spine and disc surgery. Risk factors include extraspinal infection site, urinary tract instrumentation, vascular catheter, hemodialysis, intravenous drug abuse, cancer, and diabetes mellitus**[clinical features]{.smallcaps}**---severe back pain, limited function, and fever (52%)**[diagnosis]{.smallcaps}**---MRI, blood cultures. Bone biopsy generally required for confirmation and microbiological diagnosis to guide therapy**[treatments]{.smallcaps}**---*cloxacillin* 2 g IV q4--6 h or *cefazolin* 2 g IV q8h. Consider *vancomycin* 15 mg/kg IV q12h if high local MRSA rates

### PROSTHETIC JOINT INFECTIONS {#FPar158}

**[pathophysiology]{.smallcaps}**---most commonly due to coagulase-negative staphylococci**[treatments]{.smallcaps}**---debridement with retention of prosthesis may be possible with early-onset infection (within 3 months of surgery), short duration of symptoms (\<3 weeks) with no sinus tract, a stable implant *and* a causative organism susceptible to quinolones (or trimethoprim--sulfamethoxazole) and rifampin, which are given for 3 months (hips) to 6 months (knees) after an initial course of appropriate IV antibiotic therapy for at least 2 weeks. If debridement and retention are not appropriate, removal of the infected prosthesis with one-stage or two-stage exchange; IV antibiotic therapy is also provided for 6 weeks following the initial surgery

NEJM 2009 361:8

Septic Arthritis {#Sec63}
================

See SEPTIC ARTHRITIS (p. 309)

Tuberculosis: Pulmonary {#Sec64}
=======================

[www.respiratoryguidelines.ca/tb-standards-2013](http://www.respiratoryguidelines.ca/tb-standards-2013); NEJM 2004 350:20

Pathophysiology {#Sec65}
---------------

### ORGANISMS {#FPar159}

---genus *Mycobacterium* consists of \>50 species. TB is caused by *M. tuberculosis* complex including *M. tuberculosis*, *M. bovis*, and others. The cell envelope contains mycolic acid → resists destaining by acid alcohol, thus termed acid fast bacilli

### TRANSMISSION {#FPar160}

---TB transmission is almost exclusively airborne through inhalation of minute droplet nuclei. Therefore, lungs are the primary focus. However, any organs can become infected during the bacteremia that follows initial lung infection

### LATENT TB INFECTION (LTBI) {#FPar161}

---follows initial infection; asymptomatic; detected by tuberculin skin test (TST) or interferon-gamma release assay (IGRA). Risk of active infection generally is 5% in the first 2 years with 5% risk of reactivation thereafter

### FACTORS THAT INCREASE THE RISK OF INFECTION {#FPar162}

---1/3 of the world's population is infected with TB. Birth in endemic area (less commonly travel) is the major risk factor; other risk factors include aboriginal populations and racial/ethnic minorities, household/institutional contacts and crowding (healthcare workers, long-term care, correctional facilities, substance abuse, and shelters)

### FACTORS INCREASING THE RISK OF REACTIVATION OF LTBI {#FPar163}

---HIV infection (most important risk factor, always test those with active TB for HIV), fibronodular disease on CXR, chronic renal failure, increasing age, malignancy, transplant/immunosuppression, silicosis, chronic steroid use, TNF-α inhibitors, alcohol abuse, malnutrition, liver or kidney disease, poorly controlled diabetes, smoking, gastrectomy, jejunoileal bypass

Clinical Features {#Sec66}
-----------------

### PRIMARY TB {#FPar164}

**[symptoms]{.smallcaps}**---fever, night sweats, pleuritic chest pain, chronic cough, anorexia, weight loss, fatigue, erythema nodosum**[signs]{.smallcaps}**---often none. Primary TB usually involves the mediastinal lymph nodes (Ghon complex); hilar lymphadenopathy in the presence of *RML collapse* is the most common radiologic finding (2/3) with pleural effusion in 1/3. Lung infiltrates may be seen and involve lower lungs or middle lung fields most commonly with possible cavitation in areas of consolidation

### REACTIVATION TB (active pulmonary) {#FPar165}

**[symptoms]{.smallcaps}**---subacute progressive cough, yellow-green sputum (increases over time), hemoptysis (25%), chest pain/dyspnea (33%), fever/night sweats (50%), fatigue (50--66%), weight loss**[signs]{.smallcaps}**---reactivation TB usually involves the apical-posterior segments of upper lobes (80--90%), cavitation (19--40%), hilar lymphadenopathy (more likely than cavitation in AIDS patients)**[elderly with reactivation]{.smallcaps}** **TB**---presents with fever, night sweats, or hemoptysis less often. Lesions less often cavitary and less often TST positive

### COMPLICATIONS OF PULMONARY TB {#FPar166}

---hemoptysis (rarely massive), pneumothorax (more common in endemic countries), bronchiectasis, and pulmonary destruction (rare)

### Related Topic {#FPar167}

Tuberculosis in Pregnancy (p. 473)

Investigations {#Sec67}
--------------

### BASIC {#FPar168}

**[labs]{.smallcaps}**---CBCD, lytes, urea, Cr, AST, ALT, ALP, bilirubin, albumin, urinalysis**[microbiology]{.smallcaps}**---blood C&S with mycobacterial culture, sputum Gram stain/AFB/C&S, urine AFB/C&S, HIV serology**[imaging]{.smallcaps}**---CXR, CT chest

### SPECIAL {#FPar169}

**[skin test]{.smallcaps}**---see Diagnostic Issues for details**[interferon gamma release assays]{.smallcaps}**---Quanti-FERON-TB Gold In-Tube (QFT-GIT) assay and T-SPOT TB assay**PCR[molecular fingerprinting]{.smallcaps}**---tracing outbreaks**[susceptibility testing]{.smallcaps}**---1 extra week**[thoracentesis]{.smallcaps}**---if effusion. Send for fluid AFB and TB culture**[pleural biopsy]{.smallcaps}CSF**---AFB, TB culture

Diagnostic Issues {#Sec68}
-----------------

### TUBERCULIN SKIN TEST (TST) {#FPar170}

---gold standard for diagnosing latent tuberculosis (epidemiologic tool), but not sensitive or specific to include or exclude active pulmonary TB. Given as 5 units TST-S (purified protein derivative) intradermally, measure extent of induration after 48--72 h. Skin test reaction cutoffs and corresponding population groups when test considered positive (in North America) are as follows:**0**--**4** **[mm]{.smallcaps}**---in general, considered negative; no treatment indicated unless child \<5 years of age and high risk of TB infection≥**5** **[mm]{.smallcaps}**---HIV positive, recent infectious TB contact within 2 years, CXR signs (fibronodular disease), immunosuppression (TNFα inhibitors, organ transplantation, glucocorticoid treatment equivalent of ≥15 mg/day prednisone × ≥1 month), end stage renal disease≥**10** **[mm]{.smallcaps}**---all others, including TST conversion within 2 years, diabetes, malnutrition (\<90% ideal body weight), cigarette smoking, daily alcohol consumption \>3 drinks/day, silicosis, hematologic malignancies (leukemia/lymphoma) and certain carcinomas (e.g. head and neck, lung)

Canadian Tuberculosis Standards, 7^th^ Edition 2013

### INTERFERON GAMMA RELEASE ASSAYS {#FPar171}

---sens \>95%; not affected by prior BCG vaccination. Most useful for evaluation of latent TB in those with positive TST and previously vaccinated with BCG

### SPUTUM SMEAR {#FPar172}

**[utility]{.smallcaps}**---morning sputum × 3 days (AFB, TB culture), induced sputum if necessary, bronchoscopic lavage if cannot obtain sputum. Three consecutive AFB-negative sputum samples support that patient is non-infectious and can come off isolation**[limitations]{.smallcaps}**---smear only detects 50% of culture positive TB, and in non-endemic areas positive smear may represent non-TB mycobacterium**[staining agents]{.smallcaps}**---standard is Ziehl--Neelsen (acid fast stain); Auramine--Rhodamine or Auramine O fluorescence staining improves sensitivity but must be confirmed with acid fast

### SPUTUM CULTURE {#FPar173}

---2--8 weeks in egg media, 4--14 days if radiometric (sens 80--85%, spc 98--99%)

### POLYMERASE CHAIN REACTION {#FPar174}

(PCR)---more useful in non-endemic countries to rule out other common mycobacteria. High specificity but variable sensitivity (if AFB positive, sens 94--96%, spc 99.7--100%. If AFB positive, sens 9--100%, spc 25--100%)

Management {#Sec69}
----------

### LATENT TB INFECTION {#FPar175}

---***isoniazid*** 300 mg PO daily × 6--12 months or ***rifampin*** 600 mg PO daily × 4 months. A "decision to tuberculin test is a decision to treat" with no age cutoff for treatment and regardless of BCG vaccination status. Exclude active TB with sputum culture and CXR before treatment. HIV, immunosuppressed, and newly infected patients should be priority for treatment of latent TB

### PRIMARY OR REACTIVATION TB {#FPar176}

---patients should be isolated in single rooms with negative air pressure. TB therapy should be undertaken in consultation with an expert. Susceptibility testing is necessary to guide treatment. Directly observed treatment (DOT) is the standard of care for all patients. TB therapy consists of an intensive phase of daily therapy followed by a continuation phase of twice- or thrice-weekly therapy. ★**RIPE**★ ***Rifampin*** 10 mg/kg or 600 mg PO daily, ***isoniazid*** 5 mg/kg or 300 mg PO daily, ***pyrazinamide*** 20--25 mg/kg PO daily × 8 weeks. ***Ethambutol*** 15--20 mg/kg PO daily is added until drug susceptibility results are available. This is followed by isoniazid and rifampin daily, twice weekly, or three times weekly for 16 more weeks. Alternatives include isoniazid, rifampin, pyrazinamide, plus ethambutol or streptomycin three times weekly for 24 weeks, or isoniazid, rifampin, pyrazinamide, plus ethambutol for 2 weeks, then twice weekly for 6 weeks, followed by isoniazid and rifampin twice weekly for 16 weeks (see guidelines for exceptions and alternate regimens when faced with resistance or drug intolerance)

Treatment Issues {#Sec70}
----------------

### VACCINATION WITH BCG {#FPar177}

(Bacillus Calmette-Guerin)---decreases miliary and meningeal TB by 75--86% and pulmonary TB by 50% in children. However, BCG leads to false-positive skin test, which may compromise contact tracing and decision to treat latent TB infection. Not routinely performed in areas with low endemic TB risk

### DIRECTLY OBSERVED TREATMENT {#FPar178}

---most effective method to prevent multi-drug-resistant tuberculosis according to the WHO

### MEDICATION DETAILS {#FPar179}

**[rifampin]{.smallcaps}** (RIF)---bactericidal. Side effects include hepatic toxicity (less than INH, but induces hepatic microsomal enzymes → ↑ clearance and ↓ effects of many drugs), flu-like symptoms, red-orange urine, sweat, tears**[isoniazid]{.smallcaps}** (INH)---bactericidal and inexpensive. Side effects include hepatitis (↑ with increased age and alcohol use), peripheral neuropathy (↓ with *pyridoxine* 10 mg PO daily or 25 mg PO daily if HIV, diabetes, malnourished, renal failure, pregnancy, or breast feeding)**[pyrazinamide]{.smallcaps}** (PZA)---bactericidal at acidic pH in cells. Side effects include GI intolerance, hepatic injury, hyperuricemia due to ↓ renal excretion, arthraligias**[ethambutol]{.smallcaps}**---mostly bacteriostatic. Main side effect is optic neuritis

### DRUG MONITORING {#FPar180}

**[baseline]{.smallcaps}**---platelet, Cr, AST, ALP, bilirubin, uric acid (pyrazinamide), visual acuity, and red-green color discrimination (ethambutol)**[follow]{.smallcaps}**-**[up]{.smallcaps}**---symptoms of hepatotoxicity and visual disturbance

### TREATMENT OF CO-INFECTION WITH TB AND HIV {#FPar181}

---similar treatment outcome with or without HIV, but treatment of active TB infection in HIV patients should be extended beyond 6 months if bacteriologic or clinical response is slow or suboptimal. Also beware of TB and HIV drug interactions (protease inhibitors and non-nucleoside reverse transcriptase inhibitors may cause toxic levels of rifampin, which should be replaced by rifabutin)

Approach to Gram Stain, Culture, and Sensitivity {#Sec71}
================================================

Gram-Positive Cocci {#Sec72}
-------------------

### CLUSTERS (catalase positive) (Staphylococci) {#FPar182}

**[coagulase positive]{.smallcaps}**---*S. aureus***[coagulase negative]{.smallcaps}**---*S. epidermidis*, *S. saprophyticus*, *S. hominis*, *S. lugdunesis*, *S. schleiferi*

### PAIRS/CHAINS (catalase negative) {#FPar183}

**α**-**[hemolytic streptococci]{.smallcaps}**---*S. pneumoniae*, viridians group streptococci**β**-**[hemolytic streptococci]{.smallcaps}**---*S. pyogenes* (Group A strep), *S. agalactiae* (Group B strep), group C, F, G strep**[enterococcus]{.smallcaps}**---*E. faecalis*, *E. faecium***[others]{.smallcaps}**---*Abiotrophia*, *Granulicatella* ("nutrient variant Strep"), *Leuconostoc*, *Lactococcus*, *Aerococcus*

### ANAEROBIC {#FPar184}

---*Peptostreptococcus*, *Streptococcus*, *Peptococcus*, *Anaerococcus*

Gram-Positive Bacilli {#Sec73}
---------------------

### ACID FAST (mycobacterium) {#FPar185}

---*M. tuberculosis*, *M. leprae*, *M. avium*-*intracellulare* complex, or non-tuberculous Mycobacteria (NTM, also known as mycobacteria other than TB \[MOTT\]). These organisms have Gram-positive-type cell walls, but do not stain Gram positive due to the waxy mycolic acids in the cell envelope

### SPORE FORMING {#FPar186}

**[aerobic]{.smallcaps}**---*Bacillus anthrax*, *Bacillus cereus***[anaerobic]{.smallcaps}**---*Clostridium perfringens*, *C. difficile*, *C. botulinum*

### NON-SPORE FORMING {#FPar187}

**[aerobic]{.smallcaps}**, **[facultative]{.smallcaps}**, **[aerotolerant]{.smallcaps}**---*Corynebacterium*/diphtheroids, *Lactobacillus*, *Listeria*, *Gardenerella*, *Nocardia***[anaerobic]{.smallcaps}**---*Actinomyces*, *Propionibacterium*, *Eubacterium*

### BRANCHING BACILLI {#FPar188}

---★**ABCD**-**LMN**★ ***A*** *ctinomyces* (acid fast negative), ***B*** *acillus*, ***C*** *lostridium*, **D**iphtheroids, ***L*** *isteria*, ***L*** *actobacillus*, ***M*** *ycobacterium* (modified and Ziehl--Neelsen acid fast), ***N*** *ocardia* (modified acid fast)

Gram-Negative Cocci {#Sec74}
-------------------

### NEISSERIA {#FPar189}

---*N. meningitidis* (diplococci), *N. gonorrhoeae* (diplococci), other Neisseria

### MORAXELLA {#FPar190}

---*M. catarrhalis*

Gram-Negative Bacilli {#Sec75}
---------------------

### AEROBIC {#FPar191}

**[glucose fermenting and lactose fermenting]{.smallcaps}**---a number of Enterobacteriaceae including *E. coli*, *Citrobacter*, *Enterobacter*, *Klebsiella*, *Serratia***[glucose fermenting but non]{.smallcaps}**-**[lactose fermenting]{.smallcaps}**---*Shigella*, *Salmonella*, *Hafnia*, *Morganella*, *Proteus*, *Yersinia*, *Edwardsiella*, *Vibrio* (oxidase positive), *Aeromonas* (oxidase positive), *Pleisiomonas* (oxidase positive)**[non]{.smallcaps}**-**[glucose and non]{.smallcaps}**-**[lactose fermenting]{.smallcaps}** **[oxidase positive]{.smallcaps}**---*Pseudomonas*, *Ralstonia*, *Burkholderia*, *Roseomonas*, *Sphingomonas***[oxidase negative]{.smallcaps}**---*Stenotrophomonas*, *Acinetobacter*, *Chryseomonas*

### ANAEROBIC {#FPar192}

---*Bacteroides fragilis*, *Fusobacterium*, *Prevotella*, *Porphyromonas*

### OTHERS {#FPar193}

---*Eikenella*\*, *Pasteurella* (cats), *Capnocytophaga* (dogs), *Kingella*\*, *Actinobacillus*\*, *Cardiobacterium*\*, *Haemophilus*\* (coccobacilli, pleomorphic), *Legionella* (BCYE agar), *Campylobacter* (boomerang)

\*HACEK organisms in endocarditis

Specific Organisms {#Sec76}
------------------

### NON-GRAM-STAINABLE {#FPar194}

---Chlamydia, Mycoplasma, Ureaplasma, Rickettsia, Treponema, Coxiella, Ehrlichia, Mycobacteria

Antibiotic Susceptibility and Resistance {#Sec77}
----------------------------------------

### GROUP A STREPTOCOCCAL INFECTIONS {#FPar195}

---resistant to clindamycin

### *STREPTOCOCCUS PNEUMONIAE* {#FPar196}

---may develop resistance to penicillin by altered penicillin-binding protein

### *S. AUREUS* (MSSA) {#FPar197}

---may develop resistance to penicillin by β-lactamase

### *PSEUDOMONAS* {#FPar198}

---various intrinsic mechanisms conferring resistance. Need to treat with dual antibiotic therapy for serious infections if therapy for \>2 weeks or if susceptibility not yet available

### VRE {#FPar199}

---vancomycin-resistant enterococci

### MRSA {#FPar200}

---*S. aureus* that is resistant not only to penicillin, but also penicillinase-resistant penicillins (methicillin, nafcillin, oxacillin). In general, hospital MRSA strains have broader resistance (e.g. clindamycin, trimethoprim--sulfamethoxazole, tetracyclines) than community-associated MRSA strains (CA-MRSA). Risk factors for hospital MRSA infections include frequent hospital visits and contact with MRSA-infected individuals; CA-MRSA is associated with crowding, acute and chronic skin disease, poor hygiene, sharing of contaminated items, contact sports, and IDU

### β-LACTAMASE-RESISTANT BACTERIA {#FPar201}

---**constitutive** (*E. coli*\*, *Klebsiella*\*, *Haemophilus*, *Neisseria*, *bacteroides*), **inducible** (*S. aureus*, ***S*** *erratia*†\*, ***P*** *rovidencia*†, ***P*** *seudomonas*, **Indole-positive** *Proteus*†\*, ***C*** *itrobacter*†\*, ***E*** *nterobacter*†\*, ***H*** *afnia*†\*, ***A*** *cinetobacter*†\*, ***M*** *organella*†\*)

†★**SPICE-HAM**★ organisms with inducible, chromosomally mediated cephalosporinases (AmpC type β-lactamases) resistant to penicillins, first and second generation cephalosporins, cephamycins, and β-lactamase inhibitors

\*These organisms may have extended spectrum β-lactamase (ESBL) resistant to all β-lactams except carbapenems

Gentamicin and Tobramycin Dosing {#Sec78}
--------------------------------

### TOXICITY {#FPar202}

---nephrotoxicity, ototoxicity, neuromuscular blockade (rare). Serum aminoglycoside levels correlate with nephrotoxicity

### LOADING DOSE (TRADITIONAL DOSING: Q8H) {#FPar203}

---dependent on indication. For mild infection, uncomplicated UTI, synergy with β-lactams for Gram positive infections, give 0.6--1.2 mg/kg IV q8h. For serious Gram-positive infection or sepsis, give 2.5 mg/kg IV. For life-threatening infections, give 3.0 mg/kg IV

### MAINTENANCE DOSE (TRADITIONAL DOSING: Q8H) {#FPar204}

**[start]{.smallcaps}**---1.7 mg/kg IV q8h. Monitor serum levels after steady state reached; i.e. 3--5 half-lives (after third dose). Monitor renal function and ototoxicity every 3 days**[peak levels]{.smallcaps}**---obtain 30--45 min after end of infusion. Should be 4.2--8.4 μmol/L \[2--4 μg/mL\] when drug is being given for synergy or uncomplicated infections, 12.6--16.8 μmol/L \[6--8 μg/mL\] for serious Gram-negative infection or sepsis, and 14.7--18.9 μmol/L \[7--9 μg/mL\] for life-threatening infections**[trough levels]{.smallcaps}**---obtain 0--30 min prior to scheduled dose. Should be \<4.2 μmol/L \[\<2 μg/mL\] to prevent toxicity**[adjustments]{.smallcaps}**---dosing interval is dependent on renal function (CrCl \>60 mL/min, q8h; 40--60 mL/min, q12h; 20--40 mL/min, q24h; \<20 mL/min single dose then measure serum concentration and give PRN). Changes in dose without changes in interval will result in proportional changes in both peak and trough serum drug concentrations. Prolongation of dosing interval will also reduce both, but particularly trough level

### Antibiotics {#FPar205}

AntibioticsMechanismGram positiveGram negativeAnaerobesOthersRenal adjustments**Penicillins**Penicillin G 2--4 M units IV q4--6 hBactericidal, cell wall synthesis inhibition and lysis++ StrepMeningococcus++SyphilisYes (dose + interval)Penicillin V 250--500 mg PO TID/QID++ Strep++Yes (dose + interval)Cloxacillin/nafcillin/oxacillin 1--2 g IV q4--6 h++S. aureusNo**Amino-Penicillins**Ampicillin 1--2 g IV q4--6 hBactericidal, cell wall synthesis inhibition and lysis+++Strep/Entero+/−H. flu, +/−*E coliListeria*Yes (interval)Amoxicillin 250--1,000 mg PO TID+++Strep/Entero+/−H. flu, +/−*E coli*Yes (interval)Amox/clavulanate 875/125 mg PO BID+++Strep/Entero++H. flu, *E coli*+++Yes (interval)**Anti-pseudomonal Penicillins**Piperacillin 3--4 g IV q4--6 hBactericidal, cell wall synthesis inhibition and lysis++++Pseudo++Yes (dose + interval)Pip/tazo 3.375 g q6h--4.5 g IV q8h++Staph++Pseudo/H. flu+++Yes (dose + interval)Ticarcillin 3--4 g IV q4--6 h++++Pseudo++Yes (dose + interval)Ticarcillin/clavulanate 3.1 g IV q4--6 h++++Pseudo+++Yes (dose + interval)**Monobactam and Carbapenems**Aztreonam 1--2 g IV q6--8 hBactericidal, cell wall synthesis inhibition and lysis+++Pseudo+++Yes (dose)Imipenem 500 mg IV q6h+++++Pseudo+++Yes (dose + interval)Meropenem 1 g IV q8h+++++Pseudo+++Yes (dose + interval)Ertapenem 1 g IV q24h++++(no Pseudo)+++Yes (dose)Doripenem 500 mg IV q8h++++++++Yes (dose + interval)**First-Generation Cephalosporins**Cefazolin 1--2 g IV q8hBactericidal, cell wall synthesis inhibition and lysis++++Yes (interval)Cephalexin 250--1000 mg PO QID++++Yes (interval)**Second-Generation Cephalosporins**Cefuroxime 750--1500 mg IV q8hBactericidal, cell wall synthesis inhibition and lysis++++Yes (interval)Cefuroxime 125--500 mg PO BID++++Yes (interval)Cefprozil 250--500 mg PO q12h++++Yes (interval)Cefaclor 250--500 mg PO BID++++Yes (interval)**Third/Fourth Generation Cephal.**Cefoxitin 1--2 g IV q6--8 hBactericidal, cell wall synthesis inhibition and lysis++++++++Yes (interval)Cefotaxime 1--2 g IV q6--8 h++++++Yes (interval)Ceftriaxone 1--2 g IV q24h++++++NoCeftazidime 1 g IV q8--12 h++++++PseudoYes (interval)Cefepime 1--2 g IV q12h++++PseudoYes (interval)Cefixime 400 mg PO daily+++Yes (interval)Ceftaroline 600 mg IV q8--12 h+++MRSA+++Yes (interval)**Aminoglycosides**Gentamicin 5--7 mg/kg IV q24hBactericidal, binds to 30S and 50S ribosomesEntero (syn)+PseudoYes (dose + interval)Tobramycin 5--7 mg/kg IV q24h+/--Entero (syn)++PseudoYes (dose + interval)Amikacin 7.5 mg/kg q12h+/--Entero (syn)++PseudoYes (dose + interval)Streptomycin 15 mg/kg IM or IV q24hEntero (syn)++PseudoAFB, PlagueYes (dose + interval)**Fluoroquinolones**Ciprofloxacin 500 mg PO/400 mg IV BIDBactericidal, inhibit DNA synthesis through inhibition of DNA gyrase and topoisomerase+++PseudoAFBYes (interval)Norfloxacin 400 mg PO BID+++Yes (dose ± interval)Ofloxacin 200--400 mg PO BID++AFBYes (dose ± interval)Levofloxacin 500--750 mg PO/IV daily+++++AFBYes (dose ± interval)Moxifloxacin 400 mg PO/IV daily+++++++AFBYes (dose ± interval)Gemifloxacin 320 mg PO daily+++++AFBYes (dose ± interval)**Macrolides**Azithromycin 250 mg PO dailyBacteriostatic, binds to 50S ribosomes++H. flu/legion++Mycoplasma and *Chlamydia* for all macrolid esNoClarithromycin 250--500 mg PO BID++H. flu/legionYes (dose)Erythromycin 250--500 mg PO q6--12 h++LegionNo**Tetracyclines**Doxycycline 100 mg PO/IV q12hBacteriostatic, binds to 30S ribosomes++*Chlamydia*NoMinocycline 50--100 mg PO daily-BID+++*Chlamydia*NoTetracycline 500 mg PO QID++*Chlamydia*AvoidTigecycline 100 mg IV, then 50 mg q12h+++MRSA, VRE++Acinetobacter+*Chlamydia*No**Sulfa**Sulfamethoxazole/Trimethoprim 1--2Bactericidal, blocks DNA synthesis+++Steno, +PJPYes (interval)SS/DS tab PO BID (also available IV)**Clindamycin**Clindamycin 150--450 mg PO QID or 300--600 mg IV q6--12 hBacteriostatic, binds to tRNA complex+++++No**Metronidazole**Metronidazole 500 mg PO/IV q12hBactericidal, DNA breakage*H. pylori*, *G. vaginalis*+++C. diff++protozoaNo**Glycopeptides**Vancomycin 15 mg/kg IV q12hBactericidal, interferes with peptidoglycan and RNA synthesis+++*S. epidermidis*, MRSA, Entero++C. diffYes (interval)**Oxazolidinones**Linezolid 600 mg PO/IV q12hBactericidal (Strep) and bacteriostatic (Staph, entero), binds to 50S ribosomes++MRSA, VRE+++AFBNo**Streptogramins**Quinupristin/dalfopristin 7.5 mg/kg IV q8h via central lineInhibits late + early protein synthesis++MRSA, VRE (not *E. faecalis*)+No**Lipopeptides**Daptomycin 4--6 mg/kg q24hBactericidal, disrupts cell membrane++MRSA, VRE+Yes (interval)

Once-Daily Gentamicin and Tobramycin Dosing {#Sec79}
-------------------------------------------

### RATIONALE {#FPar206}

---optimize treatment of Gram-negative infections with less nephrotoxicity than q8h dosing. Similar ototoxicity and neuromuscular toxicity

### NOT RECOMMENDED {#FPar207}

---monotherapy for infections outside urinary tract, pregnant patients, dialysis patients, endocarditis, CNS infections, osteomyelitis, ophthalmologic infections, surgical prophylaxis, patients with rapid drug clearance (e.g. burns \>20% BSA), Gram-positive infections, patients receiving concurrent ototoxins (e.g. furosemide) neonates, pediatric patients with significant renal dysfunction, duration of therapy \>14 days

### LOADING DOSE {#FPar208}

---5--7 mg/kg IV

### MAINTENANCE DOSE {#FPar209}

(5--7 mg/kg IV q24--48 h)**[start]{.smallcaps}**---monitor serum level 6--14 h after first dose. Monitor renal function and ototoxicity q3d**[adjustments]{.smallcaps}**---dosing interval (q24--48 h) is based on 6--14 h serum level (Hartford nomogram, **Antimicrob Agents Chemother 1995 39**:**3**). Pharmacy consult to assist with dosing (once daily dosing provides peak levels of 15--31--46 μmol/L \[22 μg/mL\] and trough levels \<2.1 μmol/L \[\<1 μg/mL\] to prevent toxicity. Peak and trough levels do not need to be monitored)

### DOSING WEIGHT FOR AMINOGLYCOSIDES {#FPar210}

---for obese patient (i.e. actual body weight (BW) \>125% of ideal body weight (IBW)), use adjusted body weight (ABW) for dose determination:

**ABW** (kg) = IBW +0.4(BW-IBW)

Note: 1 kg = 2.2 lbs. See p. 460 for IBW calculation

### Related Topic {#FPar211}

Drug Eruptions (p. 422)

Vancomycin Toxicity and Dosing {#Sec80}
------------------------------

### TOXICITY {#FPar212}

---rash, infusion-related red man syndrome, rarely nephrotoxicity (especially combined with aminoglycoside), and ototoxicity. However, serum vancomycin levels do not predict toxicity

### LOADING DOSE {#FPar213}

---15--20 mg/kg (usually 1--1.5 g) IV

### MAINTENANCE DOSE {#FPar214}

---30 mg/kg (actual body weight) per day divided into 2--4 doses (maximum usually 1.5 g/dose)**[start]{.smallcaps}**---monitoring after steady state, i.e. after third dose normally, or after second dose if dosing interval \>48 h. Monitor only if treatment duration \>14 days in patients with stable renal function and mild/moderate infection, or treatment duration \>4 days in patients with unstable renal function or severe infection**[trough levels]{.smallcaps}**---obtained 30--60 min before next scheduled dose. Should be at least 6.9--10.4 μmol/L \[10--15 μg/mL\]; adjust to 10.4--13.8 μmol/L \[15--20 μg/mL\] for serious infections (endocarditis, osteomyelitis)**[peak levels]{.smallcaps}**---there is no correlate for efficacy or toxicity and therefore should not be monitored**[adjustments]{.smallcaps}**---dosing interval is dependent on renal function (CrCl \>100 mL/min, q12h; 80--100 mL/min, q18h; 60--80 mL/min, q24h; 40--60 mL/min, q36h; 25--40 mL/min q48h; \<25 mL/min, single dose then measure serum concentration and give PRN). Changes in dose without changes in interval will result in proportional changes in both peak and trough serum drug concentrations. Prolongation of dosing interval will also reduce both, particularly trough level

Penicillin Allergy {#Sec81}
------------------

### HISTORY {#FPar215}

---characterize reaction (age when reaction occurred, timing of reaction after penicillin administration, type of reaction, route of administration, reason for penicillin, any other medications at the time, resolution), any similar antibiotics since

### CROSS-REACTIVITY {#FPar216}

---incidence of cross-reactivity to cephalosporins when patient has penicillin allergy by history is \<2%. Carbapenems and first/secondgeneration cephalosporins have higher cross-reactivity in the penicillin allergic than third-generation cephalosporins and aztreonam. It is often safe to use these medications, with the first dose monitored. If safety unclear, skin testing provides reassurance. For patients with a history of penicillin allergy, those with positive and negative skin test have 5.6% and 1.7% chance of developing cross-reactivity with cephalosporin, respectively

NEJM 2006 354:6

### RATIONAL CLINICAL EXAMINATION SERIES: IS THIS PATIENT ALLERGIC TO PENICILLIN? {#FPar217}

**HISTORY**---history of penicillin allergy for predicting positive response to penicillin skin test result (LR+ 1.9, LR-- 0.5), for predicting allergic response (anaphylaxis, positive skin test, or response to second course of penicillin \[LR+ \>11, LR-- 0.98\]). **TYPES OF ALLERGIC REACTIONS**★**ACID**★ **A**ntibody-mediated (IgE), **C**ytotoxic (antibody-dependent), **Immune-complex-mediated**, **D**elayed hypersensitivity reaction**[type]{.smallcaps}** **I**---immediate \<1 h, IgE antibodies mediated, anaphylaxis, hypotension, laryngeal edema, wheezing, angioedema, urticaria**[type]{.smallcaps}** **II**--- \> 72 h, IgG and complement mediated, increased clearance of RBC and platelets by lymphoreticular system**[type]{.smallcaps}** **III**--- \> 72 h, IgG and IgM immune complexes mediated, serum sickness, tissue injury**[type]{.smallcaps}** **IV**--- \> 72 h, contact dermatitis**[others]{.smallcaps}**--- \> 72 h, maculopapular or morbilliform rashes **APPROACH**---"only 10--20% of patients reporting a history of penicillin allergy are truly allergic when assessed by skin testing. Taking a detailed history of a patient's reaction to penicillin may allow clinicians to exclude true penicillin allergy, allowing these patients to receive penicillin. Patients with a concerning history of type I penicillin allergy who have a compelling need for a drug containing penicillin should undergo skin testing. Virtually all patients with a negative skin test result can take penicillin without serious sequelae"

JAMA 2001 285:19***UPDATE***---patients with a negative skin test result may still react to a repeat course of penicillin (\~10%) but the likelihood of a life-threatening reaction is greatly reduced. Patients with a well-documented immediate reaction to penicillin are \~90% likely to react with subsequent courses

The Rational Clinical Examination. McGraw-Hill, 2009

Approach to Empiric Antibiotics {#Sec82}
===============================

General Approach {#Sec83}
----------------

### CHOICE OF EMPIRIC ANTIBIOTIC {#FPar218}

---based on the most likely and deadly organisms for each type of infection. Thus, a good understanding of the pathophysiology of each infection and the local resistance pattern of various organisms is essential

### CULTURE AND SUSCEPTIBILITY {#FPar219}

---should always be performed to facilitate targeted antibiotic treatment except for mild infections. However, the specific organism may not be identified even if multiple cultures are taken. In this case, the clinician must rely on clinical judgment and continue treatment with empiric antibiotic(s)

Specific Infections and Empiric Antibiotic Choices {#Sec84}
--------------------------------------------------

### SEPSIS {#FPar220}

---depending on the suspected source. For pulmonary source, respiratory fluoroquinolone plus ceftriaxone ± vancomycin if community setting, anti-pseudomonal plus ciprofloxacin if hospital setting. For urinary source, ceftriaxone or carbapenem or fluoroquinolone or aminoglycoside. For intra-abdominal source, pipericillin--tazobactam or a carbapenem. Duration of treatment is at least 10--14 days with rationalization of antibiotics when susceptibility results available. See p. 108 for details

### MENINGITIS (*S. pneumoniae*, *N. meningitidis*, *Listeria*, HSV) {#FPar221}

---ceftriaxone/cefotaxime ± ampicillin ± vancomycin. Add acyclovir if CSF suggests viral picture. Duration of treatment is 7--21 days. See p. 269 for details

### COMMUNITY--ACQUIRED PNEUMONIA (*S. pneumoniae*, *Klebsiella*, *Mycoplasma*) {#FPar222}

---macrolides ± cefotaxime or respiratory fluoroquinolones. Duration of treatment is usually 7 days. See p. 7 for details

### ASPIRATION PNEUMONIA (anaerobes, Staph, GNB) {#FPar223}

---levofloxacin plus metronidazole. Duration of treatment is usually at least 7 days. See p. 7 for details

### ICU/VENTILATOR-ASSOCIATED PNEUMONIA (GNB, *Pseudomonas*) {#FPar224}

---ciprofloxacin plus ceftazidime or pipericillin--tazobactam or carbapenem. Duration of treatment is usually 8 days (p. 105)

### ENDOCARDITIS (*S. aureus*, *S. viridans*, *Enterococcus*) {#FPar225}

Duration of treatment is highly variable. See AHA guidelines and p. 60 for details**[native valve disease]{.smallcaps}**---ampicillin + cloxacillin/nafcillin or vancomycin plus gentamicin**[injection drug use]{.smallcaps}**---cloxacillin or vancomycin plus gentamicin**[prosthetic valve disease]{.smallcaps}**---vancomycin plus gentamicin

### ACUTE BLOODY DIARRHEA (*Salmonella*, *Shigella*, *Campylobacter*) {#FPar226}

---ciprofloxacin. Duration of treatment is 3 days. See p. 137 for details

### ANTIBIOTIC-ASSOCIATED DIARRHEA (*C. difficile*) {#FPar227}

---oral metronidazole. Duration of treatment is 10 days. See p. 138 for details

### PERITONITIS/INTRA-ABDOMINAL SEPSIS (coliforms, anaerobes) {#FPar228}

---pipericillin--tazobactam, imipenem, or ampicillin plus ciprofloxacin plus metronidazole. Treat until WBC/peritonitis resolved

### FEVER IN SPLENECTOMIZED PATIENT (*H. influenza*, *N. meningitidis*, *S. pneumoniae*, *Capnocytophaga canimorsus*) {#FPar229}

---cefotaxime/ceftriaxone. Duration of treatment is usually 10--14 days. See p. 164 for further information

### URINARY TRACT INFECTION (*E. coli*, *Klebsiella*, *Enterococcus*, *Proteus*, *S. saprophyticus*) {#FPar230}

---nitrofurantoin, trimethoprim--sulfamethoxazole, ciprofloxacin, fosfomycin. Duration of treatment is 3 days if uncomplicated UTI, otherwise 14--21 days. See p. 272 for details

### CELLULITIS (*Staphylococcus*, *Streptococcus*) {#FPar231}

---cefazolin, cloxacillin, or cephalexin. Vancomycin if MRSA suspected. Duration of treatment is usually 7--10 days. See p. 275 for details

### HUMAN BITE (Gram positive, *Eikenella*, anaerobes) {#FPar232}

---amoxicillin--clavulanate, or clindamycin plus ciprofloxacin

### DIABETIC FOOT (polymicrobial) {#FPar233}

---amoxicillin--clavulanate or ciprofloxacin plus clindamycin, or trimethoprim--sulfamethoxazole plus metronidazole. Treat until resolution. May require IV antibiotics with *Pseudomonas* coverage (e.g. pipericillin--tazobactam; carbapenem). Osteomyelitis likely if ulcer \>2 cm^2^ or probe touches bone. See p. 277 for details

### NECROTIZING FASCIITIS {#FPar234}

---surgical treatment is mandatory. For polymicrobial infection, cefotaxime plus clindamycin, pipericillin--tazobactam, or ampicillin/penicillin G plus ciprofloxacin/gentamicin plus metronidazole. For *Streptococcus*, penicillin G plus clindamycin. See p. 275 for details

### OSTEOMYELITIS (Gram positive, Gram negative, anaerobes) {#FPar235}

---for Gram-positive coverage, cefazolin, or vancomycin. For Gram-negative coverage, ceftriaxone or ciprofloxacin. For *Pseudomonas*, piperacillin or carbapenem or ceftazidime, plus ciprofloxacin or aminoglycoside. Duration of therapy usually at least 6 weeks. See p. 277 for details

### SEPTIC ARTHRITIS {#FPar236}

---vancomycin, cloxacillin, or cefazolin for Gram-positive coverage, ciprofloxacin or ceftriaxone for Gram-negative coverage. Usual duration 4 weeks. See p. 309 for details

Hepatitis B {#Sec85}
===========

See HEPATITIS B (p. 145)

Hepatitis C {#Sec86}
===========

See HEPATITIS C (p. 147)

Herpes Simplex Virus Infection {#Sec87}
==============================

See HERPES SIMPLEX VIRUS (p. 416)

Human Immunodeficiency Virus {#Sec88}
============================

<http://aidsinfo.nih.gov/guidelines>

Risk Factors for HIV {#Sec89}
--------------------

**SEXUAL CONTACT**

### PARENTERAL {#FPar238}

---IDU, transfusion, or unsafe needle use in developing world, health workers

### MATERNAL--FETAL {#FPar239}

---in-utero, delivery, breast feeding

Acute HIV Infection {#Sec90}
-------------------

### STRAINS {#FPar240}

---HIV1 globally; HIV2 mainly in West Africa

### SYMPTOMS {#FPar241}

---acute febrile "mononucleosis-like" illness, lymphadenopathy, pharyngitis, rash and headache within 1--6 weeks post-exposure. Hematologic (lymphopenia, thrombocytopenia) and liver enzyme abnormalities

### DIAGNOSIS {#FPar242}

---ELISA assay (sens \~100%, spc \<100%) → if positive, repeat ELISA → if positive, Western blot → if indeterminate, repeat Western blot 4 weeks, 3 months, and 6 months later. If during window period (2 weeks postexposure), may perform viral load testing

### BASIC WORKUP FOR THE NEWLY DIAGNOSED {#FPar243}

**HIV** **[status]{.smallcaps}**---viral load, CD4 count, genotypic antiretroviral drug resistance testing**[baseline]{.smallcaps}**---CBCD, lytes, urea, Cr, AST, ALT, ALP, bilirubin, TSH, glucose, fasting lipid profile, lipase, CK, HLA B\*5701 (for abacavir hypersensitivity), βhCG, CXR, ECG, urinanalysis**[co]{.smallcaps}**-**[existing]{.smallcaps}**/**[opportunistic infections]{.smallcaps}**---HAV serology, HBV testing (HBsAg, HBsAb, HBcAb. If HBsAg or HBcAb positive, check HBV DNA as well), HCV testing (HCV antibodies). If HCV positive, HCV RNA, assess genotype and order fibroscan. Pap smear, anal screening for HPV in men who have sex with men (MSM) (no consensus yet), *Chlamydia* and gonorrhea screen, syphilis testing, TST or IGRA, toxoplasma serology, CMV serology

Natural History of HIV {#Sec91}
----------------------

### VIRAL LOAD {#FPar244}

---rate of progression (speed of train). Indicates activity of viral replication. Critical measure of effect of antiretroviral therapy, once started

### CD4 COUNT {#FPar245}

---progress and stage of disease (distance to crash). Indicates relative health of immune system and risk of opportunistic complication

### FOLLOW-UP {#FPar246}

---viral load and CD4 count (usually 3--4-month intervals, or q2--8 weeks if change of HAART)

### AIDS {#FPar247}

---CD4 \< 200/mm^3^ or any AIDS-defining diseases**[bacterial]{.smallcaps}**---MAC, TB, recurrent *Salmonella* sepsis**[viral]{.smallcaps}**---CMV retinitis, chronic HSV, PML**[fungal]{.smallcaps}**---esophageal candidiasis, extrapulmonary coccidioidomycosis, histoplasmosis or cryptococcosis**[parasitic]{.smallcaps}**---*Pneumocystis jiroveci* pneumonia (PJP), toxoplasmosis, chronic Cryptosporidiosis or isosporiasis**[hiv]{.smallcaps}**---HIV encephalopathy, wasting syndrome**[neoplasms]{.smallcaps}**---Kaposi's sarcoma, CNS lymphoma, non-Hodgkin's lymphoma, cervical carcinoma

### MAJOR CAUSES OF DEATH IN HIV PATIENTS ON HAART {#FPar248}

---AIDS (30%), liver disease (14%), cardiovascular disease (9%), non-AIDS cancers (8%)

### CD4 COUNT AND PATHOLOGIES IN HIV PATIENTS {#FPar249}

CD4 count (/mm)^3^\>500200--500100--200\<100Kaposi sarcoma++++Bacterial++++TB++++HSV++++Candida+++Coccidioides+++Histoplasma+++PJP++Cryptococcus+Toxoplasma+CMV+MAC+CNS lymphoma+

CNS Lesions in HIV Patients {#Sec92}
---------------------------

### DIFFERENTIAL DIAGNOSIS {#FPar250}

**[brain abscess]{.smallcaps}**---toxoplasma (CD4 \< 100/mm^3^, usually multiple ring-enhancing lesions), tuberculosis (any CD4), Cryptococcus (CD4 \< 100/mm^3^), Histoplasma (CD4 \< 500/mm^3^), aspergillosis**CNS** **[lymphoma]{.smallcaps}** (CD4 \< 100/mm^3^)**[progressive multi]{.smallcaps}**-**[focal leukoencephalopathy]{.smallcaps}** (PML, CD4 \< 100/mm^3^)---reactivation of JC virus, hypodense white matter lesion

### DIAGNOSIS {#FPar251}

---CBCD, lytes, urea, Cr, blood C&S, toxoplasma IgG antibodies, EBV PCR, JC virus PCR, CT/MR head, PET scan (CNS lymphoma has higher activity than abscess), brain biopsy (if suspect CNS lymphoma). The combination of (1) multiple ring enhancing lesions, (2) positive antitoxoplasmosis antibodies, and (3) lack of toxoplasma prophylaxis in a HIV patient with CD4 count \<100/mm^3^ has 90% PPV for diagnosing toxoplasma

### TREATMENT OF TOXOPLASMOSIS {#FPar252}

---pyrimethamine plus either sulfadiazine or clindamycin

Chronic Meningitis In HIV Patients {#Sec93}
----------------------------------

### DIFFERENTIAL DIAGNOSIS {#FPar253}

**[cryptococcus]{.smallcaps}** (CD4 \< 100/mm^3^)---ubiquitous fungus. High opening pressure (\>200 cmH~2~O)**[bacterial meningitis]{.smallcaps}** (any CD4)---*N. meningitis*, *S. pneumoniae*, *Listeria*, Gram-negative bacilli**[viral meningitis]{.smallcaps}** (any CD4)---HSV encephalitis

### DIAGNOSIS {#FPar254}

---CBCD, lytes, urea, Cr, blood C&S, serum CRAG (sens 95% for Cryptococcus), CT head, lumbar puncture (for Cryptococcus and cryptoantigen)

### TREATMENT OF CRYPTOCOCCUS {#FPar255}

---induction with *amphotericin B* 0.7 mg/kg IV daily plus *flucytosine* 25 mg/kg PO QID, switch to *fluconazole* 400 mg PO daily × 2 months for consolidation, followed by *fluconazole* 200 mg PO daily as maintenance. Management of increased intracranial pressure may be needed (neuroimaging to rule out concomitant space-occupying lesions, repeated LP to decrease ICP)

Respiratory Infections in HIV Patients {#Sec94}
--------------------------------------

### DIFFERENTIAL DIAGNOSIS {#FPar256}

**[community]{.smallcaps}**-**[acquired pneumonia]{.smallcaps}** (any CD4)---most common cause is *S. pneumoniae*. Others include *Moraxella*, *H. influenzae***[tuberculosis]{.smallcaps}** (any CD4)---170× increased risk in HIV patients. May be extrapulmonary**[non]{.smallcaps}**-**TB** **[mycobacterium]{.smallcaps}**---MAC (CD4 \< 100/mm^3^, pulmonary involvement alone is rare, usually disseminated)**[fungal]{.smallcaps}** (CD4 \< 500/mm^3^)---Histoplasma, *Coccidioides*, *Cryptococcus****PNEUMOCYSTIS JIROVECII*** **[pneumonia]{.smallcaps}** (PJP, CD4 \< 200/mm^3^)

### DIAGNOSIS {#FPar257}

---CBCD, lytes, urea, Cr, LDH (↑ in PJP but non-specific), blood C&S and mycobacterial culture, sputum C&S and AFB, ABG (for PaO~2~ and A-a gradient), urine C&S, CXR, bronchoscopy (lavage, biopsy)

### TREATMENT OF PJP {#FPar258}

---*trimethoprim*--*sulfamethoxazole* 15 mg of TMP/kg PO/IV divided q8h daily × 21 days. If severe disease (PaO~2~ ≤ 70 mmHg or A-a gradient ≥ 35 mmHg on room air), add *prednisone* 40 mg PO BID × 5 days, then 40 mg PO daily × 5 days, then 20 mg PO daily × 11 days. Alternatives to *trimethoprim*--*sulfamethoxazole* include dapsone plus trimethoprim, or clindamycin plus primaquine, pentamidine IV. Use atovaquone if G6PD deficiency

Esophagitis in HIV Patients {#Sec95}
---------------------------

### DIFFERENTIAL DIAGNOSIS {#FPar259}

**[infections]{.smallcaps}** **[candida]{.smallcaps}** (CD4 \< 500/mm^3^)---50--70%**HSV** (any CD4)---5--10%**CMV** (CD4 \< 100/mm^3^)---5--15%**[non]{.smallcaps}**-**[infectious]{.smallcaps}**---GERD, pill esophagitis, neoplasms**[idiopathic]{.smallcaps}** (any CD4)---10--30%

### DIAGNOSIS {#FPar260}

---empiric therapy (fluconazole), endoscopy with cultures for fungus, virus, and biopsy

Hepatitis/Cholangitis/Pancreatitis in HIV Patients {#Sec96}
--------------------------------------------------

### DIFFERENTIAL DIAGNOSIS {#FPar261}

**[infections]{.smallcaps}** **TB** (any CD4)**[mycobacterium avium complex]{.smallcaps}** (MAC, CD4 \< 100/mm^3^)---*M. avium*, *M. intracellulare***[viruses]{.smallcaps}**---HBV, HCV, CMV**[parasites]{.smallcaps}**---Cryptosporidium, Microsporidium, Cyclospora**[alcohol]{.smallcaps}[drugs]{.smallcaps}**---antiretrovirals, antibiotics (sulfa, isoniazid, rifampin, ketoconazole, fluconazole)

### DIAGNOSIS {#FPar262}

---CBCD, lytes, urea, Cr, AST, ALT, ALP, bilirubin, lipase, INR, cultures and serologies, US abd, CT abd, ERCP

Colitis/Diarrhea in HIV Patients {#Sec97}
--------------------------------

### DIFFERENTIAL DIAGNOSIS {#FPar263}

**[infections]{.smallcaps}** **[bacterial]{.smallcaps}**---*Salmonella*, *Shigella*, *Campylobacter*, *Yersinia*, EHEC, EIEC, *C. difficile***TB** (any CD4)**[mycobacterium avium complex]{.smallcaps}** (MAC, CD4 \< 100/mm^3^)---*M. avium*, *M. intracellulare***CMV** (CD4 \< 100/mm^3^)**[parasitic]{.smallcaps}** ★**MAGIC**★---**M**icrosporidium, Ent**A**moeba, **G**iardia, **I**sospora, **C**ryptosporidium**[medications]{.smallcaps}**---antiretrovirals, antibiotics**AIDS** **[enteropathy]{.smallcaps}**---diagnosis of exclusion

### DIAGNOSIS {#FPar264}

---CBCD, lytes, urea, Cr, stool C&S, stool O&P with acid fast staining, stool MAC, C. diff toxin, fecal WBC, Cryptosporidium, microsporidium

### TREATMENT OF MAC {#FPar265}

---*clarithromycin* 500 mg PO BID or *azithromycin* 600 mg PO daily, plus *ethambutol* 15 mg/kg PO daily, plus *rifabutin* 600 mg PO daily for at least 12 months and at least 6 months of immune reconstitution (CD4 \> 100--200/mm^3^)

AIDS-Associated Malignancies {#Sec98}
----------------------------

### AIDS-DEFINING MALIGNANCIES {#FPar266}

**K** **[aposi]{.smallcaps}**'**[s sarcoma]{.smallcaps}** (any CD4)---strongly associated with HHV8. Lesions may involve skin, oral mucosa, lungs, and GI tract. Treat with liposomal doxorubicin. Lesions may also resolve with antiretroviral treatment**[non]{.smallcaps}**-**H** **[odgkin]{.smallcaps}**'**[s lymphoma]{.smallcaps}** (CD4 \< 100/mm^3^)---diffuse large B-cell lymphoma, primary effusion lymphoma (associated with HHV8 and EBV), and plasmablastic lymphomas. Treat with combination chemotherapy (CHOPR)**[primary]{.smallcaps}** **CNS** **[lymphoma]{.smallcaps}** (CD4 \< 100/mm^3^)---strongly associated with EBV. Treat with radiation and/or high-dose methotrexate or intrathecal chemotherapy**[cervical carcinoma]{.smallcaps}** (any CD4)---strongly associated with HPV. Treat with surgery, radiation, and/or chemotherapy (cisplatin)

### NON-AIDS-DEFINING MALIGNANCIES {#FPar267}

---increased incidence of Hodgkin's lymphoma, multiple myeloma, anogenital cancer, testicular cancer (seminoma), and basal cell carcinoma in HIV patients. Lung cancer, colorectal cancer, melanoma, squamous cell carcinoma of skin, and head and neck cancer may also be increased

Education, Prophylaxis, and Immunization for HIV Patients {#Sec99}
---------------------------------------------------------

### EDUCATION AND COUNSELING {#FPar268}

---patient MUST be told to reveal HIV status to sexual partners (reportable disease). Advise regarding condom use and safer sex practices. Risk reduction strategies should be explored for substance abuse (e.g. avoid sharing needles or other drug paraphenalia), tobacco use, and other social issues. HIV is a chronic disease that can be successfully treated.

### PJP PROPHYLAXIS {#FPar269}

---for patients with CD4 \< 200/mm^3^. *Trimethoprim*--*sulfamethoxazole* SS 1 tab PO daily, or *trimethoprim*--*sulfamethoxazole* DS 1 tab PO daily, or *trimethoprim*--*sulfamethoxazole* DS 1 tab PO three times a week. If allergic, desensitize or use dapsone or inhaled pentamidine

### TOXOPLASMOSIS PROPHYLAXIS {#FPar270}

---for patients with positive *Toxoplasma* serology and CD4 \< 100/mm^3^. *Trimethoprim*--*sulfamethoxazole* DS 1 tab PO daily. If allergic, dapsone plus pyrimethamine plus folinic acid are alternatives

### MAC PROPHYLAXIS {#FPar271}

---for patients with CD4 \< 50/mm^3^. *Azithromycin* 1200 mg PO once weekly

### HISTOPLASMOSIS PROPHYLAXIS {#FPar272}

---for patients with CD4 \< 150/mm^3^ and living in endemic area. *Itraconazole* 200 mg PO daily

### TB PROPHYLAXIS {#FPar273}

---for patients with positive TST reaction (induration ≥5 mm) and not treated for TB previously. *Isoniazid* 5 mg/kg/day PO daily to max 300 mg/day, or 900 mg thrice weekly × 9 months. *Rifampin* 600 mg PO daily × 4 month restricted to exposures to INH-resistant, RIF-susceptible isolates. Should be followed by a TB specialist

### VACCINATIONS {#FPar274}

**[give]{.smallcaps}**---Prevnar followed by pneumococcal polysaccharide vaccine at least 8 weeks later. Pnemococcal vaccine should be repeated every 5 years up to three doses. Hepatitis B vaccine (if non-immune), hepatitis A vaccine (if non-immune and especially if homosexual), influenza vaccine annually are all recommended**[generally avoid]{.smallcaps}**---live vaccines (oral polio, varicella, measles-mumps-rubella, or yellow fever immunizations) if CD4 count is \<200/mm^3^

### Related Topics {#FPar275}

Hepatitis B (p. 145)

Hepatitis C (p. 147)

HIV in Pregnancy (p. 473)

Needle Stick Injury (p. 304)

Tuberculosis (p. 279)

Antiretroviral Therapy for HIV Patients {#Sec100}
---------------------------------------

### NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTI) {#FPar276}

---zidovudine (ZDV, AZT), stavudine (d4T), didanosine (ddI), lamivudine (3TC), abacavir (ABC), tenofovir (TDF), and emtricitabine (FTC). Major side effects include hepatic steatosis, lactic acidosis, neuropathy, anemia, pancreatitis, and renal disease

### NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTI) {#FPar277}

---efavirenz (EFV), nevirapine (NVP), etravirine (ETR) and rilpivarine (RPV). Major side effects include rash, Stevens--Johnson syndrome, hepatitis, and CNS complications

### PROTEASE INHIBITORS (PI) {#FPar278}

---saquinavir (SQV), indinavir (IDV), nelfinavir (NFV), lopinavir--ritonavir (LPV/RTV), fosamprenavir (FPV), atazanavir (ATV), tipranavir (TPV), and darunavir (DRV). Major side effects include hyperglycemia, fat redistribution syndrome, insulin resistance, and GI intolerance

### INTEGRASE INHIBITORS {#FPar279}

---raltegravir, dolutegravir, elvitegravir

### FUSION INHIBITOR (FI) {#FPar280}

---enfuvirtide (T-20)

### CCR5 ANTAGONIST {#FPar281}

---maraviroc

### EXAMPLES OF PREFERRED HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) REGIMENS {#FPar282}

NRTI (tenofovir plus emtricitabine) plus NNRTI (efavirenz)NRTI (tenofovir plus emtricitabine) plus PI (atazanavir/ritonavir or darunavir/ritonavir)NRTI (tenofovir plus emtricitabine) plus integrase inhibitor

Therapeutic Decisions in HIV {#Sec101}
----------------------------

### GOALS OF HIV THERAPY {#FPar283}

---durable suppression of HIV viral load to undetectable levels, reduction in HIV related morbidity, improvement in quality of life, prolongation of survival, restoration of immune function, and prevention of HIV transmission

### APPROACH {#FPar284}

---start treatment in all symptomatic patients and in asymptomatic patients if CD4 \< 500/mm^3^. Treatment should be considered for all patients. Rapidly declining CD4 counts (\>100/mm^3^/year) or baseline viral loads \>100,000 copies/mL increase the urgency of treatment. Initiate HIV treatment regardless of CD4 in pregnancy, HIV nephropathy, and in those with HBV when therapy for HBV is indicated. A commitment to lifelong treatment and adherence is essential prior to initiating therapy. HIV therapy is increasingly complex and should only be undertaken by those with expertise in HIV management

### RESPONSE {#FPar285}

---successful if viral load ↓ by 2 logs after 8 weeks and ↓ to \<50 copies/mL after 6 months of therapy. Need to continue therapy or may develop viral load rebound/drug resistance. If failure, consider non-adherence and/or resistance. Resistance testing should be performed, and the regimen should be changed based on resistance profile

Immune Reconstitution Inflammatory Syndrome (IRIS) in HIV Patients {#Sec102}
------------------------------------------------------------------

### PATHOPHYSIOLOGY {#FPar286}

---delayed (1 week to several months) inflammatory response as the immune system is restored by antiretrovirals, leading to acute, paradoxical deterioration of pre-existing infections (TB, MAC, PJP, histoplasma, HCV, HBV). Clinical features highly variable. IRIS is a diagnosis of exclusion after considering drug reactions, non-adherence, new onset or progression of opportunistic infection. May occur in up to 25% of patients with opportunistic infections started on HAART (e.g. lymphadenopathy after starting antiretrovirals in patients with disseminated MAC or worsening CXR and fever in patients with TB). In general, treat opportunistic infections for 2 weeks prior to initiating antiretroviral therapy

### TREATMENTS {#FPar287}

---supportive, continue antiretrovirals, give corticosteroids

Viral Hepatitis in HIV Co-infected Patients {#Sec103}
-------------------------------------------

### HEPATITIS B {#FPar288}

**[pathophysiology]{.smallcaps}**---HIV/HBV co-infection rate is up to 20--30% in Asia/sub-Saharan Africa where transmission is mostly vertical or between young children and 5--10% in the USA and Europe where transmission is mostly via IDU and sexual contact. Co-infection is associated with increased risk of progression to end-stage liver disease**[diagnosis]{.smallcaps}**---for patients with isolated HBcAb, 10--45% have occult HBV infection with detectable levels of HBV DNA**[prevention]{.smallcaps}**---hepatitis B vaccination of family and sexual partners**[treatment]{.smallcaps}**---long-term combination therapy with a nucleoside analogue and nucleotide analogue (e.g. tenofovir plus either emtricitabine or lamivudine) is recommended in co-infected patients. Ultrasound and AFP recommended every 6 months for hepatocellular carcinoma screening

### HEPATITIS C {#FPar289}

**[pathophysiology]{.smallcaps}**---HIV/HCV co-infection rate up to 70--95% for patients with IDU and hemophilia and 1--12% for MSM. Coinfection results in more aggressive HCV, with more rapid progression to liver failure and hepatocellular carcinoma, particularly if concurrent alcohol use**[diagnosis]{.smallcaps}**---rarely may be HCV seronegative requiring PCR testing. Histologic injury as defined by liver biopsy or fibroscan is a much better predictor of clinical outcomes than liver enzymes or HCV viral load and may be useful in selected patients to guide therapy**[prevention]{.smallcaps}**---risk reduction and safer needle use**[treatment]{.smallcaps}**---for HCV is rapidly changing. New directly acting agents are replacing interferon and ribavirin as the drugs of choice for treatment of HCV with increased rates of cure and fewer side effects (see Chapter on Hepatitis C for more details. p. 290)

Influenza {#Sec104}
=========

NEJM 2008 359:24

Differential Diagnosis {#Sec105}
----------------------

### VIRAL {#FPar290}

---influenza A/B/C, parainfluenza, RSV, metapneumovirus, adenovirus, rhinovirus

### BACTERIAL PNEUMONIA {#FPar291}

---*Streptococcus pneumoniae*, *Staphylococcus aureus*, *Haemophilus*, *Moraxella*

### ATYPICAL {#FPar292}

---*Mycoplasma*, *Chlamydia*, *Legionella*, TB, community-acquired MRSA

Pathophysiology {#Sec106}
---------------

### CLASSIFICATION {#FPar293}

---the three types of influenza are A, B, and C. Influenza A can be classified into various subtypes based on the combination of two surface glycoproteins: neuraminidase (1 of 9 subtypes) and hemagglutinin (1 of 16 subtypes), e.g. H1N1, H1N2, and H3N2. Influenza A subtypes and influenza B can be further classified into various strains that arise due to antigenic drift

### HOSTS {#FPar294}

---influenza B and influenza C viruses mainly affect humans. In contrast, influenza A can infect both humans and animals, including wild birds, poultry, pigs, dogs, and horses. Some influenza A strains are highly pathogenic and can cause severe disease in specific hosts, while others are associated with low pathogenicity. The process whereby at least two different viral strains combine to form a new subtype with a mixture of surface antigens of the original strains is termed antigenic shift and is the source of pandemic influenza virus

### ANTIGENIC DRIFT {#FPar295}

---a gradual change in viral RNA sequence that occurs in both influenza A and B. This process is due to random point mutations in the genes encoding neuraminidase or hemagglutinin, creating strains of virus with new surface glycoproteins. Thus, antibodies against previous strains are ineffective. Can result in seasonal epidemics

### ANTIGENIC SHIFT {#FPar296}

---an abrupt and significant emergence of novel viral strains. Only happens in influenza A. Antigenic shift occurs through mixing of human influenza A and animal (e.g. pig, bird) influenza A virus genes to create a new human influenza A subtype through a process called genetic reassortment (e.g. swine flu, avian flu). Rarely, avian strains of influenza may directly infect humans. Antigenic shift generates new virus and triggers pandemics as the majority of the population has no immunity against this new virus

### PANDEMIC {#FPar297}

(worldwide outbreak)---based on the following criteria: (1) emergence of a new subtype of influenza A virus, (2) this virus is able to infect humans, (3) this virus can spread easily from person to person in a sustained manner

### DISTINGUISHING FEATURES BETWEEN INFLUENZA A, B, AND C {#FPar298}

Influenza AInfluenza BInfluenza CHostsHumans, Birds, MammalsHumans onlyHumans, SwineAntigenic shiftYes, creating new subtypesNoNoAntigenic driftYes, creating new strainsYesYesEpidemicsYesYesNoPandemicsYesNoNo

Clinical Features {#Sec107}
-----------------

### SYMPTOMS {#FPar299}

---acute onset of systemic symptoms, such as fever, headache, myalgia, arthralgia, fatigue, and respiratory symptoms such as cough, dyspnea, and sore throat

### COMPLICATIONS {#FPar300}

---**respiratory** (bacterial pneumonia), **muscular** (rhabdomyolysis, myositis), **neurologic** (encephalitis, aseptic meningitis, transverse myelitis, Guillain--Barre syndrome)

### RATIONAL CLINICAL EXAMINATION SERIES: DOES THIS PATIENT HAVE INFLUENZA? {#FPar301}

Sens (%)Spc (%)LR+LR--All age groupsFever----1.80.4Feverishness----1.00.7Cough----1.10.42Myalgia----0.931.2Malaise73260.981.1Headache----1.00.75Sore throat----1.00.96Sneezing----1.20.87Nasal congestion----1.10.49Chills83251.10.68Vaccine history----0.631.1Fever and cough64671.90.54Fever, cough, and acute onset63682.00.54Rapid influenza testing----4.70.06**Age** ≥**60**Fever34913.80.72Feverishness47782.10.68Cough----2.00.57Myalgia----2.40.68Malaise57782.60.55Headache----1.90.70Sore throat----1.40.77Sneezing32330.472.1Nasal congestion47500.951.0Chills46822.60.66Vaccine history----0.631.1Fever and cough30945.00.75Fever, cough, and acute onset27955.40.77 **APPROACH**---"clinical findings identify patients with influenza-like illness but are not particularly useful for confirming or excluding the diagnosis of influenza. Clinicians should use timely epidemiologic data to ascertain if influenza is circulating in their communities, then either treat patients with influenza-like illness empirically or obtain a rapid influenza test to assist with management decisions"

JAMA 2005 293:8

Investigations {#Sec108}
--------------

### BASIC {#FPar302}

**[labs]{.smallcaps}**---CBCD, lytes, urea, Cr, AST, ALT, ALP, bilirubin, urinalysis**[microbiology]{.smallcaps}**---nasopharyngeal swab for rapid assays (variable sensitivity/specificity), RT-PCR (preferred), or DFA (direct fluorescent antigen detection). Blood C&S, sputum Gram stain/AFB/C&S, urine C&S**[imaging]{.smallcaps}**---CXR

### SPECIAL {#FPar303}

**[lumbar puncture]{.smallcaps}**---if neurologic symptoms**ABG**

Management {#Sec109}
----------

### PREVENTION IS KEY {#FPar304}

---annual vaccination for the following individuals: 50 or older, children 6--24 months or taking long-term salicylates, any chronic medical condition, pregnant women, healthcare workers, household contacts of those at risk, and residents of chronic care facilities. In some jurisdictions, universal vaccination for influenza is recommended. Depending on the match between vaccine and circulating virus, the efficacy can range from 70 to 90% for a good match and 0 to 50% for poor matches

### TREATMENT {#FPar305}

---neuraminidase inhibitors (*oseltamivir* 75 mg PO BID × 5 days, or *zanamivir* 10 mg inhaled BID × 5 days) are active against influenza A and B. Antiviral treatment is most effective when started within 48 h of symptom onset. Treatment decreases the duration of symptoms by 1 day, reduces viral shedding, and may reduce complications in those at risk. Inhaled zanamivir is relatively contraindicated in patients with asthma or chronic respiratory conditions. Household contacts of infected individuals should be vaccinated and may be given prophylaxis with *oseltamivir* 75 mg PO daily or *zanamivir* 10 mg inhaled daily × 10 days. Resistance to oseltamivir is a problem in some strains of influenza A, and amantadine or rimantidine may have a role. Treatment of secondary bacterial pneumonia with antibiotics

Treatment Issues {#Sec110}
----------------

### NEURAMINIDASE INHIBITORS {#FPar306}

---neuraminidase plays an important role for viral release from the host cell. Oral oseltamivir and inhaled zanamivir are active against both influenza A and influenza B

### ADAMANTANES {#FPar307}

---block replication of influenza A RNA through inhibition of M2 protein ion channels. Amantadine and rimantadine are inactive against influenza B and C and resistance is now widspread in influenza A

### VACCINE PRODUCTION {#FPar308}

---every February/March, the World Health Organization makes recommendations regarding the three strains (two A and one B) of influenza viruses that are most likely to cause outbreaks in the fall/winter in the upcoming season. Vaccines are then produced based on this decision

Antiviral Agents {#Sec111}
================

Antiviral agentsMechanismHSV, VZVCMVInfluenza AInfluenza BAcyclovir 200--800 mg PO BID 5×/day; 5--10 mg/kg IV q8hNucleoside analogues---activated by viral thymidine kinase, inhibit viral DNA polymerase (vDNAp); also incorporated into viral DNA and act as a chain terminator++Valacyclovir 500--1000 mg PO daily--TID++Famciclovir 250--1000 mg PO BID++Penciclovir 10 mg/g topically q2h × 4 daysApplied topically for treatment of oral cold sores++Ganciclovir 5 mg/kg IV q12h or 1000 mg PO TID (maintenance)Nucleoside analogue that inhibits viral DNA polymerase++++Valganciclovir 900 mg PO daily--BID+++++Foscarnet 90 mg/kg IV q12--24 hPyrophosphate analogue that inhibits viral DNA polymerase+++++Cidofovir 5 mg/kg IV q weekNucleoside analogue that inhibits viral DNA polymerase+++++Amantadine 100 mg PO BIDInhibit M2 Protein (ion channel) of influenza A, blocking uncoating of virus genome within newly infected cells++Rimantadine 100 mg PO BID++Zanamivir 10 mg INH q12--24 hNeuraminidase Inhibitors. Block release of influenza virus from infected cells++++Oseltamivir 75 mg PO daily--BID++++

Fungal Infections {#Sec112}
=================

General Approach {#Sec113}
----------------

### CLASSIFICATION {#FPar309}

---fungal infections can be classified into three main categories: yeasts, molds ("filamentous fungi"), and dimorphic fungi**[yeasts]{.smallcaps}**---grow as single cells (via budding) and include *Candida*, *Malassezia*, *Rodotorula*, *Trichosporon***[molds]{.smallcaps}**---these filamentous fungi grow as hyphae (via sexual and asexual reproduction) and include *Aspergillus*, zygomycetes, *Fusarium*, and dematiaceous (pigmented) fungi. Ubiquitous in the environment (e.g. soil, decaying vegetation, water, air). Infection may cause blood vessel invasion, thrombosis, and obstruction. Clinical syndromes include cerebral parenchymal infections, pulmonary parenchymal infections, hepatosplenic abscesses, and otitis externa**[dimorphic fungi]{.smallcaps}**---exist as both molds and yeasts and include *Coccidioides*, *Histoplasma*, *Blastomyces*, and *Cryptococcus*. At low temperatures, found as multicellular molds (which release spores that are inhaled). In warm temperatures (e.g. inside the body), inhaled spores germinate into yeasts, which are infectious to the patient, but no longer contagious (i.e. these patients do not require isolation)

Candidiasis {#Sec114}
-----------

### PATHOPHYSIOLOGY {#FPar310}

---*Candida albicans* ("Germ-tube positive" with pseudohyphae) or non-albicans species ("Germ-tube negative," e.g. *C. glabrata*, *C. tropicalis*, *C. parapsilosis*, *C. krusei*), mostly in patients with hematological malignancy, neutropenia, on immunosuppressants, IDU, or those in the intensive care unit with hemodialysis, broad-spectrum antibiotics, surgery, central venous catheters, and parenteral nutrition

### CLINICAL FEATURES {#FPar311}

---localized mucocutaneous infections (thrush and vaginitis), serious focal infections (endophthalmitis, meningitis, osteomyelitis), or disseminated infection (candidemia) with pustular skin lesions, retinal lesions. Candiduria is common in ICU patients, but usually represents colonization unless patient is symptomatic

### TREATMENTS {#FPar312}

**[oropharyngeal]{.smallcaps}**---*clotrimazole troche* 10 mg 5× daily, *nystatin* suspension (500,000 U) or *nystatin pastilles* (200,000 U) 4× daily, *fluconazole* 100 mg PO/IV daily × 1--2 weeks**[esophagitis]{.smallcaps}**---*fluconazole* 400 mg loading dose, then 200 mg PO/IV daily × 2--3 weeks**[candiduria]{.smallcaps}**---remove catheter, indications for treatment include kidney transplant recipients, prior to cystoscopy or invasive GU procedure, neonates, severe illness, and possibly neutropenia (controversial). *Fluconazole* 200 mg PO/IV daily × 2 weeks**[acute disseminated candidemia]{.smallcaps}**---remove all intravascular devices. *Fluconazole* 800 mg IV loading dose, then 400 mg PO/IV daily × 2 weeks (minimum), or one of the echinocandins, including *caspofungin* 70 mg then 50 mg IV daily, *micafungin* 100 mg IV daily, or *anidulafungin* 200 mg loading, then 100 mg IV daily × 2 weeks (minimum) after last positive culture for *C. albicans*. Echinocandin and lipid formulation of amphotericin B are preferred for initial therapy in neutropenic patients. Almost all (\>95%) *C. albicans* are sensitive to fluconazole. Some laboratories report *C. albicans* as "*C. albicans complex*" because of structural resemblance between *albicans* and *dubliniensis*. This is of no clinical significance because *albicans* and *dubliniensis* have the same susceptibility patterns. Susceptibility patterns for other non-albicans infections may significantly differ. Consider echinocandin for non-albicans Candidiasis

CID 2009 48:5

Aspergillosis {#Sec115}
-------------

### MICROBIOLOGY {#FPar313}

---genus contains \>185 species including *A. fumigatus* (80% of clinical infections), *A. flavus*, *A. niger*, *and A. terreus*

### PATHOPHYSIOLOGY {#FPar314}

---mostly in patients with neutropenia, organ or stem cell transplants, advanced AIDS, or on corticosteroids. Invasive aspergillosis has mortality of \>50%

### CLINICAL FEATURES {#FPar315}

---spectrum of pulmonary involvement includes colonization, pulmonary aspergilloma ("fungal ball"), allergic bronchopulmonary aspergillosis (ABPA), chronic necrotizing aspergillus pneumonia (CNPA), and invasive aspergillosis. Second most common cause of fungal endocarditis (after *Candida*). Cutaneous involvement may follow trauma or dissemination from respiratory tract

### DIAGNOSIS {#FPar316}

---often difficult and may require biopsy with culture and histology. Check quantitative immunoglobulin, aspergillus IgG and IgE, galactomannan levels (suggestive of invasive aspergillosis). CT chest may show multiple nodular lesions (halo sign = nodule with surrounding hemorrhage, air crescent sign = necrosis and cavitation). Sputum fungal culture and eosinophils, bronchoalveolar lavage, or lung biopsy. The galactomannan assay is relatively specific for invasive aspergillosis, and, in the right clinical context, provides adequate evidence of invasive pulmonary disease. This assay can be done on serum or BAL specimens

### TREATMENTS {#FPar317}

---*voriconazole* 6 mg/kg q12h × 24 h then 4 mg/kg IV q12h or 200 mg PO BID until resolved. Alternatives include *caspofungin* 70 mg then 50 mg IV q24h, lipid-formulation *amphotericin B* 3--5 mg/kg IV daily, *micafungin* 100--150 mg IV daily, *posaconazole* 200 mg PO QID then 400 mg BID after clinical stabilization. Some species, especially *A. terreus*, are resistant to amphotericin. *Aspergillus* is the only filamentous fungus that can be treated with echinocandins

CID 2008 46:3

Clin Infect Dis. 2009 49:11

J Clin Microbiol. 2010 48:4

Zygomycetes (Mucormycosis) {#Sec116}
--------------------------

### MICROBIOLOGY {#FPar318}

---large group of filamentous fungi including *Rhizopus*, *Absidia*, *Rhizomucor*, *Mucor*, and *Cunninghamella*

### PATHOPHYSIOLOGY {#FPar319}

---mostly affecting immunocompromised patients and those with diabetes. Prognosis extremely poor

### CLINICAL FEATURES {#FPar320}

---CNS, pulmonary, GI, and cutaneous involvement. Infection can cause devastating rhino-orbital-cerebral and pulmonary infections

### TREATMENTS {#FPar321}

---antifungal therapy frequently needs to be combined with surgical debridement. Empiric treatment options include lipid formulations of amphotericin B and pozaconazole. Note that susceptibility testing of Zygomycetes is not always reliable, and that caspofungin and "azoles" (apart from pozaconazole) are not generally effective

Histoplasmosis {#Sec117}
--------------

### PATHOPHYSIOLOGY {#FPar322}

---*H. capsulatum* endemic along St. Lawrence seaway and in Midwestern states located along the Ohio and Mississippi River valleys. Symptoms typically occur in patients who are immunocompromised or exposed to a large inoculum

### CLINICAL FEATURES {#FPar323}

---usually asymptomatic. Pulmonary manifestations may mimic sarcoidosis and include pneumonia (localized or diffuse), granuloma/cavitary lung lesions, and hilar and mediastinal lymphadenopathy. Pericarditis, arthritis, arthralgia and erythema nodosum may also occur without pulmonary symptoms. Disseminated disease may present with hepatosplenomegaly, pancytopenia, oropharyngeal ulcers, skin, and CNS involvement

### DIAGNOSIS {#FPar324}

---fungal culture of blood and tissue, urine antigen, *Histoplasma* serology, and histopathology. *Histoplasma* is predominantly an intracellular pathogen; therefore cultures need to be placed in "isolator tube" (containing cell lysis product)

### TREATMENTS {#FPar325}

---*itraconazole* 200 mg PO TID × 3 days, then 200 mg PO daily--BID, lipid formulation of amphotericin B (preferred for ill patients)

CID 2007 45:7

Cryptococcosis {#Sec118}
--------------

### MICROBIOLOGY {#FPar326}

---formerly believed to be unicellular yeast, although now confirmed to be dimorphic. Unlike other dimorphic fungi (e.g. *Histoplasma*, *Blastomyces*, *and Coccidioides*), *Cryptococcus* is ubiquitous and not geographically isolated. *Cryptococcus neoformans* has two varieties: *C. neoformans* var. *neoformans* and var. *gattii*

### PATHOPHYSIOLOGY {#FPar327}

***[C. neoformans]{.smallcaps}***---almost invariably in immunocompromised patients including HIV with CD4 \< 100/mm^3^, transplantation, hematologic malignancies, chronic kidney diseases, diabetes mellitus, cirrhosis, or corticosteroid use. This pathogen is inhaled, then disseminates with predilection for CNS with meningitis more common than focal parenchymal infections***C***. ***[gattii]{.smallcaps}***---seen more commonly in immunocompetent hosts and paradoxically uncommon in immunosuppressed hosts. Symptomatic infection is usually pulmonary ± focal parenchymal brain infection

### CLINICAL FEATURES {#FPar328}

---CNS, pulmonary, and cutaneous involvement (but may involve any organ)

### TREATMENTS {#FPar329}

---**CNS infection** (lumbar puncture to lower intracranial pressure, amphotericin B plus flucytosine, followed by fluconazole), **pulmonary or cutaneous infection** (fluconazole or itraconazole)

CID 2010 50:3

Coccidioidomycosis {#Sec119}
------------------

### PATHOPHYSIOLOGY {#FPar330}

---endemic to lower deserts of southern Arizona, central California, southwestern New Mexico, and west Texas in USA. Also Mexico, Central and South America. Peak incidence from May--July and October--December. Affects mostly patients with immunosuppression

### CLINICAL FEATURES {#FPar331}

---an acute pulmonary infection that is often asymptomatic, but can cause a flu-like illness or pneumonia. Pulmonary symptoms include chest pain, cough, fever, and hemoptysis if cavitary lesions. Radiologically, unilateral infiltrate and hilar adenopathy are common. Cutaneous symptoms include erythema nodosum and erythema multiforme. Most common sites of dissemination are skin, bone, and meninges

### DIAGNOSIS {#FPar332}

---fungal culture and serology. Note that *Cocciodioides* is a level 3 pathogen. Therefore, cultures should be processed in high-level isolation unit and labeled carefully. There have been numerous reports of iatrogenic infection of laboratory personnel when adequate precautions not taken

### TREATMENTS {#FPar333}

---usually resolves spontaneously if uncomplicated disease. Antifungal therapy may need to be combined with surgery for certain pulmonary infections. *Fluconazole* 400 mg PO daily, *itraconazole* 200 mg PO daily (duration dependent on site of infection and may last months to years). *Coccidioides* meningitis should be treated with amphotericin B

CID 2005 41:9

Blastomyces {#Sec120}
-----------

### PATHOPHYSIOLOGY {#FPar334}

---mostly found in northwest Ontario, the Great Lakes, and some Eastern states (e.g. Ohio, Mississippi River valley). Infection occurs by inhalation of aerosolized spores from soil

### CLINICAL FEATURES {#FPar335}

---asymptomatic infection is common. Pulmonary symptoms of acute or chronic pneumonia (incubation time 45--100 days). Extrapulmonary dissemination to skin, bone/joint, GU tract, usually associated with pulmonary disease

### DIAGNOSIS {#FPar336}

---fungal culture. Presence of "broadbased budding yeast" in clinical specimens strongly suggests *Blastomyces*

### TREATMENTS {#FPar337}

---amphotericin B or lipid formulation for moderate to severe disease or CNS involvement. Itraconazole for mild disease or step-down but has poor blood--brain barrier penetration; alternatives are voriconazole or fluconazole

CID 2008 46:12

Indications for Voriconazole {#Sec122}
----------------------------

### INVASIVE ASPERGILLOSIS {#FPar338}

---first line treatment for invasive and CNS

### INVASIVE CANDIDIASIS {#FPar339}

---second or third line treatment for patients who are refractory or intolerant of fluconazole (first line for some).

### FUNGEMIA {#FPar340}

---empiric treatment for fungi not yet speciated where neither amphotericin B nor fluconazole can be used

### FEBRILE NEUTROPENIA {#FPar341}

---empiric antifungal treatment for patients with suspected aspergillus infection

Indications for Caspofungin/Micafungin {#Sec123}
--------------------------------------

### INVASIVE ASPERGILLOSIS {#FPar342}

---third line treatment for patients who are refractory or intolerant of voriconazole (first line) or amphotericin B (second line)

### INVASIVE CANDIDIASIS {#FPar343}

---second line treatment for patients who are refractory or intolerant of fluconazole (first line for some)

### FUNGEMIA {#FPar344}

---empiric treatment for fungi not yet speciated where neither amphotericin B nor fluconazole can be used

### FEBRILE NEUTROPENIA {#FPar345}

---empiric antifungal treatment

Treatment Definitions {#Sec124}
---------------------

### REFRACTORY {#FPar346}

---persistence of positive cultures OR lack of clinical response despite ≥5 days of therapy and removal of catheter if applicable

### INTOLERANCE {#FPar347}

---serum creatinine doubling from baseline AND ≥450 μmol/L \[≥5.1 mg/dL\], tripling of serum creatinine from baseline, creatinine clearance ≤40 mL/min or concomitant administration of nephrotoxins, documented allergy, or intolerable infusion reactions

Antifungal Agents {#Sec121}
=================

MechanismCandidaCryptococcusAspergillusOther molds^a^Dimorphic^b^Zygomycota^c^Renal adjustmentsAzolesFluconazole^d^ 100--400 mg PO/IV dailyInhibits CP450 (convert lanosterol to ergosterol on cell membrane)++C. alb++++Yes (dose)Itraconazole^e^ 100--200 mg PO daily--BID+++++++++NoVoriconazole^f^ 4 mg/kg IV q12h or 200 mg PO BID++++++++Fusa/Scedo++No but avoid IV formPosaconazole 200 mg PO QID++++++++++++Fusa+++++No**Amphotericin B** ^**g**^Amphotericin B 0.3--1 mg/kg IV q24hBinds to ergosterol on cell wall, causing cell leakage+++++++++++++++Yes (interval)Liposomal AmphoB 3--5 mg/kg IV q24h+++++++++++++++Yes (interval)AmphoB colloidal dispersion+++++++++++++++Yes (interval)AmphoB lipid complex 5 mg/kg IV q24h+++++++++++++++Yes (interval)**Echinocandin** ^**h**^Caspofungin 70 mg then 50 mg IV q24hInhibits synthesis of β-1,3-d-glucan on cell wall+++++++Scedo+/--NoMicafungin 150 mg IV q24h++++++NoAnidulafungin 200 mg then 100 mg IV q24h++++++No**5**-**Flucytosine**5 FlucytosineInhibits synthesis of DNA (thymidylate synthetase)++++++++Yes (dose)^a^other than *Aspergillus*, *Fusarium*, *Scedosporium*, and *Pseudallescheria boydii* are all examples of molds^b^dimorphic fungi include *Histoplasma capsulatum*, *Coccidioides immitis*, *Blastomyces dermatitidis*, *Paracoccidioides brasiliensis*, and *Sporothrix schenckii*^c^zygomycota fungi include *Rhizopus*, *Mucor*, and *Absidia*^d^fluconazole is ineffective against some *Candida*, molds, and *Zygomycetes*^e^itraconazole is ineffective against some *Candida*, *Scedosporium*, and *Zygomycetes*. It has activity against *Cryptococcus*, but has less CSF penetration than fluconazole^f^voriconazole is ineffective against some *Candida*, *Scedosporium*, and *Zygomycetes*. It has activity against *Cryptococcus*, but has less CSF penetration than fluconazole^g^amphotericin B is ineffective against molds (*Fusarium*, *Scedosporium*, *Trichosporum*, *Aspergillus terreus*), *C. guilliermondii* and *C. lusitaniae*^h^caspofungin is ineffective against *Zygomycetes*, *Cryptococcus*, and *Fusarium* but probably has activity against other molds

Infection Control {#Sec125}
=================

Nosocomial Infections {#Sec126}
---------------------

### DEFINITION {#FPar348}

---infections acquired in hospital that occur between 48 and 72 h after admission and up to 72 h after discharge (up to 30 days for surgical procedures)

### URINARY TRACT INFECTIONS {#FPar349}

---secondary to urinary catheters. Infection rates are 1--5%, up to 100% for long-term catheterization. Complications include cystitis, prostatitis, pyelonephritis, and urosepsis

### VENTILATOR-ASSOCIATED PNEUMONIAS {#FPar350}

---secondary to mechanical ventilation (after \>48 h, p. 105)

### BACTEREMIA {#FPar351}

---secondary to central venous catheters. Infection rates are 3--7%

### SURGICAL SITE INFECTIONS {#FPar352}

---secondary to incisions

### PREVENTION STRATEGIES {#FPar353}

---hand washing, hand washing, and hand washing! Education, isolation, and surveillance are important. Practice routine/standard/universal precautions with the use of gloves when handling all body fluids except sweat. Always use sterile technique when inserting urinary and central venous catheters. Minimize NG tube insertion and keep patient head of bed 30--45° if intubated

### ISOLATION {#FPar354}

**[airborne]{.smallcaps}** (negative pressure room with high-efficiency particulate aerator filter, certified N95 respirator for personal protection)---varicella, tuberculosis, measles. Negative pressure room required**[droplet]{.smallcaps}** (mask within 3--6 ft; eye protection)---*H. influenzae*, *N. meningitidis*, influenza, RSV, pertussis, parainfluenza, adenovirus, human metapneumovirus and other respiratory viruses**[contact]{.smallcaps}** (glove, gown, wash hands)---*C. difficile*, VRE, MRSA, carbapenem-resistant organism (CRO), ESBL

### *N. MENINGITIDIS* PROPHYLAXIS {#FPar355}

**[chemoprophylaxis]{.smallcaps}**---for exposures in last 7 days with *ciprofloxacin* 500 mg PO × 1 dose or *rifampin* 600 mg PO BID × 2 days can be used to reduce the risk of *N. meningitidis* in "close contacts." Vaccines are not recommended for primary prophylaxis post-exposure, but may be useful for epidemic control on a population basis**[close contacts]{.smallcaps}**---defined as healthcare workers with direct exposure to respiratory secretions (e.g. mouth-to-mouth resuscitation or intubation), household members, intimate contacts, children in school environments, coworkers in the same office, young adults in dormitories, and recruits in training centers. Not recommended for most medical personnel (i.e. those without direct exposure to patient's oral secretions) or for casual or indirect contacts (e.g. school or workmates)

Needle Stick Injury {#Sec127}
-------------------

### PREVENTION {#FPar356}

---routine/standard/universal precautions (gloves, gowns, masks if risk of exposure of body fluids), never recap needles, education

### PRE-EXPOSURE PROPHYLAXIS {#FPar357}

---immunization (hepatitis B vaccine at 0, 1, 6 months)

### RISK OF TRANSMISSION {#FPar358}

---depends on the mechanism of exposure, source patient characteristics, pre and post-exposure prophylaxis**HBV**---6--30% if source positive. Transmission via urine, feces, and saliva unlikely**HCV**---1.8% if source positive. Transmission via urine and feces unlikely**HIV**---0.3% if source positive. Transmission via urine, feces, and saliva unlikely

### POST-EXPOSURE PROCEDURE {#FPar359}

**[source patient testing]{.smallcaps}**---HBV, HCV, HIV**[exposed person baseline testing]{.smallcaps}**---HBV, HCV, HIV (ELISA, Western), CBCD, lytes, urea, Cr, AST, ALT, ALP, bili**HBV** **[prophylaxis]{.smallcaps}**---HB Ig (only if source patient is HBsAg positive or unknown and the exposed person is unvaccinated) and start vaccination for HBV**HIV** **[prophylaxis]{.smallcaps}**---antiretroviral therapy for 30 days (if source patient HIV positive or source patient unknown and high risk). Therapy may include raltegravir and truvada (tenofovir/emtricitabine). If source patient ARV resistance testing known, post-exposure procedure can be tailored accordingly. Treatment should be started within 4 h**[counseling]{.smallcaps}**---protective sexual intercourse, hold blood donation and breastfeeding, side effects of prophylactic medication(s), follow-up in 2 weeks

<http://www.health.alberta.ca/documents/PEP-Guidelines-2013.pdf>

### PROPHYLAXIS FOR OTHER INFECTIOUS AGENTS {#FPar360}

--- diphtheria (penicillin or erythromycin), pertussis (trimethoprim--sulfa, erythromycin), rabies (rabies immune globulin, vaccine), varicella zoster (varicellazoster immune globulin, vaccine), hepatitis A (immune globulin, vaccine)

Immunization for Adults {#Sec128}
=======================

<http://www.phac-aspc.gc.ca/publicat/cig-gci/p03-02-eng.php>

VaccineTypeScheduleIndicationsContraindications**Viral vaccines**Measles SCLive0, +1 months (if high risk)All adults not previously immunized in childhoodPreg, immunocomp.Mumps SCLive0, +1 months (if high risk)All adults not previously immunized in childhoodPreg, immunocomp.Rubella SCLive0, +1 months (if high risk)All adults not previously immunized in childhoodPreg, immunocomp.Polio IM/SCInactivated--Not routinely recommended for adults--HBV IMRecombinant0, +1 months, +6 monthsAll adults not previously immunized in childhood, particularly high-risk groups for parenteral or sexual exposure, chronic liver disease (e.g. chronic HCV/HBV), chronic renal disease, healthcare workers, MSM, household and sexual contacts of those with chronic HBV, those with or evaluated for STDs--HAV IMInactivated0, +6 monthsTravelers (esp. developing world), chronic liver disease (e.g. chronic HCV/HBV), MSM, ?food handlers--Influenza IMInactivatedAnnually (Oct)Adults \>50 year, \>6 month-50 years with chronic disease, pregnancy, healthcare workersVaricella SCLive0, 1--2 monthsAll who have not had chicken pox by adulthood, especially healthcare workersPreg, immunocomp.Herpes zoster SCLive1 doseAdults \>60 years. Note this vaccine has higher dose of attenuated virus than varicella vaccinePreg, immunocomp, no history of VaricellaHPV IMRecombinant0, +1--2 months, +6 monthsFemales aged 9--26 years (licensed also for males in some countries) Controversial as outcomes data pending--**Bacterial vaccines**PertussisCellular1 doseAll adults not previously immunized in childhood; single dose of acellular Pertussis vaccine combined with Tetanus/diphtheria (Tdap) recommended for adults aged 19--64--Td (tetanus, diphtheria) IMToxoid, inactivated0, +2 months, +6--12 months, q10 yearAll adults not previously immunized in childhood (see Tdap under Pertussis)--Pneumococcal IM/SCPolysaccharide0, +5 yearAdults \>65 years, \>6 months--50 years with chronic disease, pregnancy, splenectomy, malignancy, smokers--Haemophilus type BConjugated1 doseSplenectomy--Meningococcal SCPolysaccharide1 doseSplenectomy, college dormitory students, lab workers, travelers to endemic areas--

Principles {#Sec129}
----------

### RISK FACTORS FOR SPECIFIC ORGANISMS {#FPar361}

**HBV**---household contacts/sexual partners of hepatitis patients, IDU, homosexual, multiple sexual partners, tattoo, piercing, transfusions, healthcare workers (prior to vaccine era), residents/workers of institutions for mentally ill or criminals, birth in endemic country**HCV**---sexual partners (controversial), IDU, tattoo, piercing, transfusions, residents/workers of institutions for mentally ill or criminals**[pneumococcal]{.smallcaps}**, **[meningococcal]{.smallcaps}**, **[haemophilus influenzae]{.smallcaps}**---splenectomy

### CONTRAINDICATIONS {#FPar362}

**[all vaccines]{.smallcaps}**---anaphylaxis, severe illness**[live vaccines]{.smallcaps}**---pregnancy, immunocompromised (steroids, AIDS but not HIV, malignancies)

### SIDE EFFECTS {#FPar363}

---local erythema, fever
